10-009186
#6

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :
C12Q 1/70, [illegible]00, G01N 33/53
C07H 15/12, [illegible]7/00, C12N 15/00
C12P 21/06, C12N 5/00
C12Q 1/68, A61K 39/00

A1

(11) International Publication Number: WO 91/08310

(43) International Publication Date: 13 June 1991 (13.06.91)

(21) International Application Number: PCT/US90/06887

(22) International Filing Date: 26 November 1990 (26.11.90)

(30) Priority data:
442,027 27 November 1989 (27.11.89) US

(71) Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC. [US/US]; 6840 East Broadway Boulevard, Tucson, AZ 85710 (US).

(72) Inventors: PIENIAZEK, Norman, J. ; 420 Hunt River Way, Suwanee, GA 30174 (US). SLEMENDA, Susan, B. ; 2346 South Hairston, Decatur, GA 30035 (US). PIENIAZEK, Danuta ; 420 Hunt River Way, Suwanee, GA 30174 (US). VELARDE, Jorge ; 4975 Brighton Avenue #4, San Diego, CA 92107 (US). LUFTIG, Ronald, B. ; 5120 Pike, Metairie, LA 70003 (US).

(74) Agent: SCOTT, Anthony, C.; Scully, Scott, Murphy & Presser, 400 Garden City Plaza, Garden City, NY 11530 (US).

(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: DETECTION OF HUMAN ADENOVIRUS



Protein coding regions in the E3-fiber area of the human enteric adenovirus type 41 Tak (map position of fragment shown: 74% to 92%)

(57) Abstract

The present invention relates to DNA and proteins of human Adenovirus Type 41 and their use in detection of said virus. More specifically, the present invention relates to the isolation of a 41.4 kd short fiber protein and a 60.6 kd long fiber protein of Adenovirus Type 41 (Ad41), as well as protein derived from the Ad41 E3 region, thereby providing virus-derived antigens and active derivatives and parts thereof, useful in the development of diagnostic assays, DNA probes and vaccines for said virus or other related viruses belonging to the human enteric family.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing internati nal applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CI	Côte d'Ivoire	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

DETECTION OF HUMAN ADENOVIRUS

The present invention relates to DNA and proteins of human adenovirus type 41 and methods of detection thereof. In particular, the present invention relates to the isolation of a 41.4 kd fiber protein ("short" fiber protein) and a 60.6 kd fiber protein ("long" fiber protein) of human adenovirus type 41 (Ad41), as well as proteins derived from the Ad41 E3 region, thereby providing virus-derived antigens and active derivatives and parts thereof, useful in the development of diagnostic assays, DNA probes and vaccines for said virus or other related viruses belonging to the human enteric adenovirus family. The present invention is further directed to recombinant DNA molecules containing the Ad41 long fiber protein gene, the Ad41 short fiber protein gene and the Ad41 E3 gene (encoding the proteins RL-1 to RL-6) thereby providing a source of recombinant viral components useful in the development of said diagnostic assays for Ad41. The present invention is also directed to first antibodies specific to the above-identified Ad41 viral components and to second antibodies specific to the first antibodies. These second antibodies are also useful in the development of diagnostic assays for Ad41 and other adenoviruses.

Adenoviruses are simple DNA-containing viruses (i.e., composed of only DNA and protein) that multiply in the cell nucleus of the host. These viruses induce latent or acute infections in tonsils, adenoids, lungs, bladder and cornea as well as the gastrointestinal tract and are readily activated. Several adeno-

viruses are the first common viruses of humans shown to be oncogenic for lower animals under special experimental circumstances. The adenoviruses may serve as "helpers" for adeno-associated viruses which cannot replicate in their absence.

The viral particles of the adenovirus have a dense central core and an outer coat known as the capsid. These particles have an icosahedral configuration and are composed of 252 capsomers: 240 hexons make up the faces and edges of the equilateral triangles and 12 pentons comprise the vertices. The hexons are truncated triangular or polygonal prisms with a central hole. The pentons are more complex, consisting of a polygonal base with an attached fiber protein, whose length (i.e., short or long) varies with viral type. Minor capsid proteins are also associated with the hexons or pentons and confer stability on the capsid to form links with the core proteins, and to function in virion assembly.

Each virion contains one linear, double-stranded DNA molecule associated with proteins to form the core of the adenovirus.

The early region 3 (E3) of adenoviruses plays a critical role in pathogenesis of the virus's disease process even though none of its gene products are essential for replication of the virus in cell cultures. Not all proteins coded in the E3 regions of adenoviruses have been identified, even for the most commonly studied adenovirus, type 2 (Ad2). However, it has been postulated that they mediate cellular or immunological responses through structural or functional homology to regulatory molecules. For this reason, it is

possible that proteins generated from the E3 region, or their derivatives, can be used in therapy as modulators of the immune response (e.g., as an immunostimulation system in AIDS patients) or as anti-cancer agents to modify the action of various growth factors. In addition, specific E3 proteins can be used to distinguish between different adenovirus types.

Adenoviruses are widespread in nature. The 89 accepted members of the adenovirus family have similar chemical and physical characteristics and a family cross-reactive antigen but are distinguished by antibodies to their individual type-specific antigens: at least 41 are from humans and the rest from various animals.

The enteric adenoviruses, such as Adenovirus Type 40 or 41 (and also known as Type F Enteric Adenoviruses), are a virus group that cause serious intestinal and diarrheal diseases of young children. In 1978, the World Health Organization initiated a program for global prevention and control for such childhood diseases. As a result, the relative importance of various pathogens in the etiology of diarrhea in many parts of the world has been recognized. For example, rotaviruses, which rank as the most prevalent viral pathogen in childhood diarrhea, may now be close to control as many vaccines are now in sight. This has been made possible through very intensive research over the past decade.

However, the control of enteric adenoviruses, which are responsible for at least 15% of all cases of severe infantile gastroenteritis, is not yet within reach. Although they are second after rotaviruses as viral agents causing this type of infection, enteric adenoviruses remain a poorly defined group of viruses. The

paucity of research done on enteric adenoviruses is mainly due to the difficulty of propagating the viruses in cultures. For this reason, there is no sensitive, fast, and diagnostic procedure able to distinguish between enteric adenoviruses and other adenoviruses (Group A, B, C, D, and E) which are commonly present in stools but are not agents of gastroenteritis. Another reason for studying enteric adenoviruses is their possible link to intestinal cancer which appears later in the life of infected individuals.

The standard reference methods for diagnosis of enteric adenoviruses have been (1) immunoelectron microscopy; (2) type-specific neutralization; (3) growth differences on primary human and Graham-293 cells. None of these methods are accurate and suitable for rapid routine use. Recently a new commercially available enzyme-linked immunoabsorbent assay (ELISA) to detect enteric adenoviruses (Adeno-Type 40/41 EIA, Cambridge Bioscience) based on a polyclonal antibody to enteric adenovirus hexon protein was created, but this kit lacks both specificity and sensitivity.

However, the present invention solves the problems associated with the previous methodologies. The present invention describes a recombinant DNA molecule which can produce at least one of Human Adenovirus Type 41 Tak (Ad41) short fiber protein, long fiber protein, or proteins RL-1 to RL-6 of the Ad41 E3 region. (There are presently several isolates known of human adenovirus type 41, but the most common isolate of this adenovirus is human adenovirus type 41 Tak, represented in the present invention. This isolate is the standard Ad41 strain and it is listed in the American Type Culture collection under catalog number ATCC #VR-930.)

The Ad41 short and long fiber protein gene and Ad41 E3 proteins are useful for assays for human enteric adenoviruses since they express only minor immunological cross-reactivity between adenoviruses belonging to different serotypes; they are unique adenovirus proteins (i.e., Ad41 long fiber protein and possibly the short fiber as well are responsible for attachment of the virus to specific cellular receptors in the cell membrane during infection) and they express selective type-specific antigenicity. The genes of the present invention are ideal candidates for specific, selective monoclonal antibodies based on an enzyme immunoassay EIA) kit, a DNA probe assay system and a vaccine derived from the gene products. The present invention will not only enhance the understanding of the mechanism by which human enteric adenoviruses cause disease in humans, but will also assist in developing molecular probes for diagnosis of such infections.

The present invention relates to an isolated nucleic acid encoding a protein selected from human adenovirus type 41 Tak long fiber protein, short fiber protein, E3 RL-1 protein, E3 RL-2 protein, E3 RL-3 protein, E3 RL-4 protein, E3 RL-5 protein or E3 RL-6 protein. The present invention also relates to a replicable expression vector comprising the nucleic acid encoding a protein selected from human adenovirus type 41 Tak long fiber protein, short fiber protein, E3 RL-1 protein, E3 RL-2 protein, E3 RL-3 protein, E3 RL-4 protein, E3 RL-5 protein or E3 RL-6 protein operably linked to a nucleotide sequence capable of effecting an expression of a polypeptide encoded by any one of said nucleic acids.

The present invention further relates to a recombinant protein of human enteric adenovirus Type 41 wherein said protein is long fiber protein, short fiber protein, RL-1, RL-2, RL-3, RL-4, RL-5 or RL-6.

In addition, the present invention relates to a polypeptide comprising an antigenic fragment of human adenovirus Type 41 long fiber protein, short fiber protein, RL-1 protein, RL-2 protein, RL-3 protein, RL-4 protein, RL-5 protein or RL-6 protein. Also the present invention relates to antibodies against a long fiber protein of human adenovirus Type 41, a short fiber protein, RL-1 protein, RL-2 protein, RL-3 protein, RL-4 protein, RL-5 protein or RL-6 protein.

Further, the present invention relates to a vaccine for immunization against a human adenovirus comprising the administration of a mixture of inactivated Ad41 and at least one of recombinant Ad41 long fiber protein, recombinant Ad41 short fiber protein and recombinant Ad41 E3 proteins RL-1 to RL-6 or active fragments thereof in association with a conventional vaccine carrier.

Another aspect of the invention relates to a method of detecting or diagnosing human adenovirus comprising contacting serum, tissue, or tissue extracts of an individual to be tested with an antibody against Ad41 long fiber protein, short fiber protein, RL-1 protein, RL-2 protein, RL-3 protein, RL-4 protein, RL-5 protein or RL-6 protein or an active fragment thereof, for a time and under conditions necessary to form an antibody-antigen complex, and detecting any resultant antibody-antigen complex.

Yet another aspect of the invention is a method for detecting human adenovirus Type 41, human adenovirus Ad40 or any adenovirus antigenically or structurally similar to human AD41 in infected cells in a sample comprising lysing said cells, fixing the DNA of the infected cells and detecting the DNA containing said long fiber protein gene, short fiber protein gene or E3 gene by a specific probe nucleic acid wherein said probe nucleic acid is DNA, cDNA, recombinant DNA or RNA.

Still another aspect of this invention is a compartmentalized kit for detection of human adenovirus type 41 comprising at least one first container adapted to contain an antibody having specificity for Ad41 long fiber protein, short fiber protein or E3 proteins RL-1 to RL-6 and at least one second container adapted to contain a reporter molecule capable of detecting the antibody of said first container.

Fig. 1 is a representation of the DNA sequence of the human enteric adenovirus Type 41 Tak long fiber protein gene, and the corresponding amino acid sequence of Ad41 long fiber protein.

Fig. 2 is a representation of the DNA sequence of the human enteric adenovirus Type 41 Tak short fiber protein gene.

Fig. 3 is a representation of the amino acid sequence of Ad41 short fiber protein.

Fig. 4 is a representation of the DNA sequence of the human enteric adenovirus Type 41 Tak E3 gene.

Fig. 5 is a representation of the amino acid sequence of Ad41 RL-1 protein.

Fig. 6 is a representation of the amino acid sequence of Ad41 RL-2 protein.

Fig. 7 is a representation of the amino acid sequence of Ad41 RL-3 protein.

Fig. 8 is a representation of the amino acid sequence of Ad41 RL-4 protein.

Fig. 9 is a representation of the amino acid sequence Ad41 R-L-5 protein.

Fig. 10 is a representation of the amino acid sequence of Ad41 RL-6 protein.

Fig. 11 is a representation of a map of the protein coding regions in the E3 region and fiber (short and long) area of the human enteric adenovirus type 41 Tak. The E3 region is represented by proteins RL-1 to RL-6. The map position of the fragment shown is 74% to 92%.

The present invention contemplates identification, isolation and utilization of structural components of Type F Adenoviruses. In particular, the present invention relates to the human adenovirus Type 41 Tak (Ad41) long fiber protein gene, short fiber protein gene, and the entire E3 gene, and

diagnostic assays, monoclonal and polyclonal antibodies, DNA probes, and vaccines prepared relative thereto. This invention provides the advantage of a previously unavailable source of virus particles and parts thereof, and antigenic determinants and parts thereof, being highly desirable for its medical and experimental utility

In accordance with the present invention, the Ad41 long fiber protein gene, the Ad41 short fiber protein gene and the Ad41 E3 gene have been obtained by DNA sequencing of selected clones from an Ad41 library using standard techniques.

With respect to the Ad41 fiber protein gene coding for a 60.6 kd Ad41 fiber protein, henceforth this will be referred to in the Specification and Claims, as "Ad41 long fiber protein" and "Ad41 long fiber protein gene". In particular, this Ad41 long fiber protein gene found in the 1.9 Kb SmaI-EcoRI DNA fragment (map position 86.4% to 92%) of the human enteric Ad41 strain Tak was cloned in pBluescript II and sequenced directly using custom oligonucleotide primers. The gene coding for the Ad41 long fiber protein was identified using the sequence of Ad5 fiber protein gene as a reference. The procedure is outlined in more detail in the Examples.

In general, the fiber protein gene has three structural domains, the tail, the shaft and the knob, (i.e., NH_2 [N-terminus] - tail, shaft, knob - COOH [C-terminus]). Of these three domains, the "knob", which is responsible for the interaction of the virus with the cellular receptors displayed the lowest homology with other human adenoviruses such as Ad2, Ad3, Ad5, and Ad7 at the DNA or protein level.

A 650 bp Hind III/Eco RI DNA fragment coding for the "knob" domain is subcloned on pUC18 vector and used in standard Southern hybridization with DNAs of representative serotypes of the Adenovirus subgroups A, B, C, D, E, and F. Only human enteric adenoviruses Ad 40 and Ad 41 of Type F can be detected.

The dsDNA sequence of the Ad41 long fiber protein gene and subsequent amino acid sequence of Ad41 long fiber protein is represented in Fig. 1. Ad41 long fiber protein shows a high degree of homology with Ad40 fiber protein, except for the shaft region. The Ad41 long fiber protein gene shaft contains 22 typical amino acid repeats, whereas Ad40 has only 21 such repeats. (This refers to the fact that all fiber protein genes sequenced to date have shown a characteristic 15-residue motif, which is repeated 6 to 12 times and detection of this motif has aided rapid recognition of the sequence.) There is 97.7% homology between the amino acid sequence of Ad41 long fiber protein and Ad40 fiber protein in the knob region.

Further analysis has shown that the long fiber protein gene as represented in Fig. 1, starting from the N-terminus (from the left in Fig. 1 or from the 5' end of the DNA) is composed of the domains discussed above and set forth in further detail below.

(i) "Tail". It is 126 bases long (from base at position 201 to 326). On the protein level, it has 42 amino acid residues (from Met [Methionine] to Pro [Proline]). The "tail" anchors the fiber in the penton base on the virion surface and show a high degree of homology between all adenoviruses.

(ii) "Shaft". It is 1038 bases long (from base at position 327 to 1364). On the protein level it has 346 amino acid residues (from Gly [Glycine] to Leu [Leucine]). The "shaft" is a structural part of the fiber and is composed of repeating units (about 15 amino acids in each unit) showing high structural (but not sequence) homology among all adenoviruses. The number of these repeating units determines the length of fiber protein. In the case of Ad5, Ad2 and Ad41, there are 22 such units; in the case of Ad3 and Ad7, 6 units; and in Ad40, 21 units.

(iii) "Knob". It is 525 bases long (from base at position 1365 to 1889). On the protein level, it has amino acid residues (from Trp [Tryptophan] to Gln [Glutamic acid]). The TAA sequence ending the DNA sequence of the fiber gene (bases 1887-1889) is a part of the gene, but is not translated into an amino acid; it is a termination (or nonsense) codon. The "knob" region is responsible for the interaction of the virus with cellular receptors and determines the specificity of the virus. It differs substantially from adenovirus to adenovirus, depending on the types of cells infected by the virus.

The sequences flanking the Ad41 long fiber protein gene found in Fig. 1 contain various regulatory signals.

With respect to the previously undiscovered 41.4 kd Ad41 protein gene and subsequent protein encoded therein, these are henceforth characterized in the Specification and Claims as "Ad41 short fiber protein gene" and "Ad41 short fiber protein".

It was surprisingly found when sequencing the DNA of the human enteric adenovirus type 41 Tak genome upstream of the Ad41 long fiber protein gene, using standard techniques, that an open reading frame of 387 amino acids existed coding for the heretofore undisclosed Ad41 short fiber protein. The first 42 amino acids of the Ad41 short fiber protein show a high degree of homology both to Ad41 (74%) and Ad2 (61%) 60.6 kd long fiber protein tail domains. Furthermore, amino acids 43 to 233 of the short fiber protein form a typical shaft domain of twelve 15-residue repetitive motifs which is in contrast to 22 such repeats found for Ad2, Ad5, and the long fiber protein of Ad41 or 6 repeats found for Ad3 and Ad7. The knob domain (amino acids 234 to 387) is about 15% shorter than found for the above mentioned viruses. If this gene is expressed, Ad41 would resemble avian adenoviruses which were found to have two fibers of different length protruding from their pentons. The sequence presented in Fig. 2 is from the EcoRV site at map position 83.1% to the AccI site at map position 87.1%. This region was cloned and sequenced in a manner that described above.

The structure of the short fiber shows the same structural elements as described for other fiber genes (but not the identical sequence), namely:

(i) "Tail". It is 126 bases long (from base at position 157 to 282). On the protein level, it has 42 amino acid residues (from Met [Methionine] to Pro [Proline]).

(ii) "Shaft". It is 573 bases long (from base at position 283 to 855). On the protein level it has 191 amino acid residues (from Gly [Glycine] to Ile [Isoleucine]). The short fiber of Ad41 has 12 repeating units.

(iii) "Knob". The short fiber "knob" of Ad41 is 465 bases long (from base at position 856 to base at position 1320). On the protein level, it has 154 amino acids (from Trp [Tryptophane] to Gln [Glutamine]). The TAA sequence ending the short fiber protein gene (bases 1318-1320) is a part of the gene, but is not translated into an amino acid; it is a termination codon.

The knob region of the Ad41, short fiber protein is very different from the knob region of the long fiber protein as well as from knob regions of fiber proteins of other adenoviruses.

This enteric adenovirus (Ad41) is understood to use two different receptors on the surface of a cell for binding and/or penetration. It is also understood that two different fibers with distinct "knobs" permit the Ad41 virus to infect at least two different types of cells in the gastrointestinal tract. Therefore the present invention also relates to diagnostic immunoassays and effective vaccines which utilize the different Ad41 fiber proteins as discussed in further detail below.

In addition, the present invention also contemplates another critical sequence, the DNA sequence of the Ad41 E3 region as shown in Fig. 3. This will be referred to in the Specification and Claims as the Ad41 E3 gene.

In addition, the amino acid sequences of six putative proteins encoded by this region are described herein, and referred to in the Specification and Claims as RL-1, RL-2, RL-3, RL-4, RL-5 and RL-6 as set forth in further detail below.

The Ad41 E3 region DNA sequence has 3373 bases, including the flanking regions. The sequence disclosed herein is from the EcoRI restriction site at map position 74% to the EspI restriction site at map position 83.9%.

The Ad41 E3 region codes for some unique, previously unrevealed proteins. The Ad41 E3 region contains information sufficient to code for at least 6 proteins; in the following order (from the left, or 5' end):

(1) The region from base 683 to base 1204 codes for a 19.4 kd protein, referred to herein as RL-1. This protein has 173 amino acid residues. It is unique for Ad41.

(2) The region from base 1207 to 2037 codes for a 31.6 kd protein, referred to herein as RL-2. This protein has 276 amino acid residues. It is unique for Ad 41.

(3) The region from base 1730 to 1909 codes for a 6.7 kd protein (in a different reading frame than the 31.6 kd protein), referred to herein as RL-3. This protein has 59 amino acid residues and is unique for Ad41.

(4) The region from base 2056 to base 2328 codes for a 10.1 kd protein, referred to herein as RL-4. This protein as 90 amino acid residues and shows 40% homology to an Ad 2 10.4 kd protein. It was postulated by Carlin, et al., Cell, 57:135-144 (1989) that the same protein in Ad2 induces internalization and degradation of the epidermal growth factor receptors (EGF-R) .

(5) The region from base 2325 to base 2648 codes for a 12.3 kd protein, referred to herein as RL-5. This protein has 107 amino acid residues and shows 35% homology to an Ad2 14.5 kd protein; the function of the Ad2 protein is unknown.

(6) Finally, the region from base 2641 to base 3009 codes for a 14.0 kd protein, referred to herein as RL-6. This protein has 122 amino acid residues and shows 50% homology to an Ad2 14.7 kd protein which was found by Gooding, et al., Cell, 53:341-346 (1988) to inhibit cytolysis by the tumor necrosis factor (TNF).

The present invention contemplates the use of the Ad41 long and short fiber protein genes, and the Ad41 E3 region gene, via production of their gene products, to prepare antibodies. Such antibodies may be monoclonal or polyclonal. Additionally, it is within the scope of this invention to include second antibodies (monoclonal or polyclonal) directed to the first antibodies discussed above.

Accordingly, the pesent invention relates to a method for stimulating an immune response to human adenovirus type 41 Tak which consists of administering an effective amount of at least one of Ad41 long fiber protein, Ad41 short fiber protein, and Ad41 E3 proteins RL-1, RL-2, RL-3, RL-4, RL-5 and RL-6, under conditions as described below, sufficient to cause the production of polyclonal or monoclonal antibodies to at least one of said Ad41 proteins, wherein the dosage effective amount of said Ad41 proteins can be from about 0.001 mg to 100 mg.

In order to produce such antibodies, Ad41 long fiber protein, Ad41 short fiber protein or Ad41 E3 proteins (RL-1 to RL-6) are first purified, and methods of antibody production are described below. Both polyclonal and monoclonal antibodies are obtainable by immunization with at least one of the above-identified proteins or their active components (which, in the case of the fiber proteins, can be the tail, shaft or knob). The methods of obtaining both types of antibodies are well known in the art; e.g., extensive protocols for antibody production can be found in Harlow, et al., Antibodies: A Laboratory Manual, Cold Spring Harbor, N.Y., 1988. Polyclonal antibodies are less preferred, but are relatively easily prepared by injection of

a suitable laboratary animal with, for example, 0.001 to 100 mg of the purified viral antigenic component, collecting serum from the animal, and isolating specific sera by any of the known immunoadsorbent techniques. Although antibodies produced by this method are utilizable in virtually any type of imunoassay, they are generally less favored because of the potential heterogeneity of the product.

In another embodiment of the present invention, monoclonal antibodies are contemplated for detection and diagnosis of Ad41 and related adenoviruses.

The production of monoclonal antibodies relative to the present invention is particularly preferred because of the ability to produce monoclonal antibodies in large quantities and the homogeneity of the final product. The preparation of hybridoma cell lines for monoclonal antibody production derived by fusing an immortal cell line and lymphocytes sensitized against the immunogenic preparation can be done by techniques which are well known to those who are skilled in the art. (See, e.g., Kohler, G. and Milstein, C., Nature 256: 495-497, 1975; European Journal of Immunology, 6:511-519, 1976; the teachings of which are herein incorporated by reference).

Unlike preparation of polyclonal sera, the choice of animal is dependent on the availability of appropriate immortal lines capable of fusing with lymphocytes thereof. Mouse and rat have been the animals of choice in hybridoma technology and are preferably used. Humans can also be utilized as sources for sensitized lymphocytes if appropriate immortalized human (or nonhuman) cell lines are available. For the purpose of the present invention the animal of

choice may be injected with, for example, a preferred range from about 1 mg to about 20 mg of the purified virus or antigenic component thereof. (A range of 0.001 mg to 100 mg of purified viral component is also contemplated.) Usually the injecting material is emulsified in Freund's complete adjuvant. Boosting injections may also be required. The detection of antibody can be carried out by testing the antisera with appropriately labeled antigen. Lymphocytes can be obtained by removing the spleen or lymphnodes of sensitized animals in a sterile fashion and carrying out fusion. Alternately, lymphocytes can be stimulated or immunized in vitro, as described, for example, in C.Reading, J. Immunol. Meth. 53: 261-291, 1982.

A number of cell lines suitable for cell fusion , have been developed, and the choice of any particular cell line for hybridization protocols in the production of monoclonal antibodies is directed by any one of a number of criteria such as speed, uniformity of growth characteristics, deficiency of its metabolism for a component of the growth medium, and potential for a good fusion frequency.

Intraspecies hybrids, particularly between like strains, work better than interspecies fusions. Several cell lines are available, including mutants selected for the loss of ability to secrete myeloma immunoglubulin. Included among these are the following mouse myeloma lines: MPC11-X45-6TG, P3-NS1-1-Ag4-1, P3-X63-Ag8, or mutants thereof such as X63-Ag8.653, SP2-0-Ag14 (all BALB/C-derived), Y3-'Ag1.2.3 (rat), and U266 (human).

Cell fusion can induced either by virus, such as Epstein-Barr on Sendai virus, or polyethylene glycol. Polyethylene glycol (PEG) is the most efficacious agent for the fusion of mammalian somatic cells. PEG itself may be toxic for cells, and various concentrations should be tested for effects on viability before attempting fusion. The molecular weight range PEG may be varied from 1,000 to about 70% w/w in saline or serum-free medium. Exposure to PEG at 37°C for about 30 seconds is preferred in the present case, utilizing murine cells. Extremes of temperature (i.e. about 45°C) are avoided, and preincubation of each component of the fusion system at 37°C prior to fusion gives optimum results. The ratio between lymphocytes and malignant cells range of from about 1:1 to about 1:10 gives good results.

The successfully fused cells can be separated from the myeloma line by any technique known by the art. The most common and preferred method is to choose a malignant line which is Hypoxanthine Guanine Phosphoribosyl Transferase (HGPRT) deficient, which will not grow in an aminopterin containing medium used to allow only growth of hybrids and which is generally composed of hypoxanthine $1x10^{-4}M$, aminopterin $1x10^{5}M$, and thymidine $3x10^{-5}M$, commonly known as the HAT medium. The fusion mixture can be grown in the HAT-containing culture medium immediately after the fusion 24 hours later. The feeding schedules usually entail maintenance in HAT medium for two weeks and then feeding with either regular culture medium or hypoxanthine, thymidine containing medium.

The growing colonies described above are tested for the presence of monoclonal antibodies that recognize the antigenic preparation, wherein said antigenic preparation which includes at least one of the above-identified Ad41 proteins or a derivative thereof. Hybridoma antibodies are identified by using an assay where the antigen is bound to a solid support and allowed to react to hybridoma supernatants containing putative antibodies. The presence of antibodies is shown by "sandwich" techniques using a variety of indicators, as discussed in further detail below. Most of the common methods are sufficiently sensitive for use in the range of antibody concentrations secreted during hybrid growth.

Cloning of antibody-secreting hybrids can be carried out after 21-23 days of cell growth in selected medium. Cloning can be performed by cell limiting dilution in fluid phase or by directly selecting single cells growing in semi-solid agarose. For limiting dilution, cell suspensions are diluted serially to yield a statistical probability of having only one cell per well. For the agarose technique, hybrids are seeded in a semisolid upper layer, over a lower layer containing feeder cells. The colonies from the upper layer may be picked up and eventually transferred to wells.

Antibody-secreting hybrids can be grown in various tissue culture flasks, yielding supernatants with variable concentrations of antibodies. In order to obtain higher concentrations, hybrids may be transferred into animals to obtain inflammatory ascites. Antibody-containing ascites can be harvested 8-12 days after intraperitoneal

injection. The ascites contain a higher concentration of antibodies but include both monoclonals and immunoglobulins from the inflammatory ascites. Antibody purification may then be achieved by, for example, affinity chromatography. The present invention further contemplates the use of the above-described antibodies in a detection assay (immunoassay) for human enteric adenoviruses (Group F), particularly Ad41 and Ad40.

A wide range of immunoassay techniques are available as can be seen by reference to U.S. Patent Nos. 4,016,043, 4,424,279, 4,018,653 and by Harlow, et al., supra. This, of course, includes both single-site and two-site,or "sandwich", assays of the non-competitive types, as well as in traditional competitive binding assays. Sandwich assays are among the most useful and commonly used assays and are favored for use in the present invention. A number of variations of the sandwich assay technique exist, and all are intended to be encompassed by the present invention.

In a typical forward assay, an unlabeled antibody is immobilized in a solid substrate and the sample to be tested brought into contact with the bound molecule. After a suitable period of incubation, for a period of time sufficient to allow formation of an antibody-antigen binary complex, a second antibody, labeled with a reporter molecule capable of producing a detectable signal is then added and incubated, allowing time sufficient for the formation of a ternary complex of antibody-labeled antibody. Any unreacted material is washed away, and the presence of the antigen is determined by observation of the visible signal produced by the reporter molecule. The results may either be

qualitative, by simple observation of the visible signal, or may be quantitated by comparing with a control sample containing known amounts of hapten.

Variations on the forward assay include a simultaneous assay, in which both sample and labeled antibody are added simultaneously to the bound antibody, or a reverse assay in which the labeled antibody and sample to be tested are first combined, incubated and then added to the unlabeled surface bound antibody. These techniques are well known to those skilled in the art, and the possibility of minor variations will be readily apparent to those skilled in the art.

As used herein, "sandwich assay" is intended to encompass all variations on the basic two-site technique. For example, these antibodies may be used to detect Ad41 by its long and/or short fiber proteins or any one of E3 proteins RL-1 to RL-6 or other antigenically related adenoviruses (i.e., Ad40) by use of specific antigenic determinants, or parts thereof (i.e., Ad41 fiber proteins, or the tails, shafts or knobs of said proteins) as immobilized immunoadsorbants. Serum is obtained from subjects to be tested and said serum contacted to the immobilized viral immunoadsorbants. If said serum contains antibodies to said immunoadsorbants, an antibody-adsorbant conjugate will result. After removing excess serum and non-bound antibodies, a second antibody specific to a first antibody, said first antibody being capable of forming a conjugate with said immunoadsorbant, is added thus resulting in a double antibody-adsorbant conjugate. This double antibody-adsorbant conjugate will only result if the test serum contains antibodies to the immunoadsorbant. Consequently, standard detection techniques can be used to identify the conjugate.

In another immunoassay, the competitive binding assay, a limiting amount of antibody specific for the molecule of interest (either an antigen or hapten) is combined with specific volumes of solutions containing an unknown amount of the molecule to be detected and a solution containing a detectably labeled known amount of the molecule to be detected or an analog thereof. Labeled and unlabeled molecules then compete for the available binding sites on the antibody. Phase separation of the free and antibody-bound molecules allows measurement of the amount of label present in each phase, thus indicating the amount of antigen or hapten in the sample being tested. A number of variations in this general competitive binding assay currently exist.

In any of the known immunoassays, for practical purposes, one of the antibodies to the antigen (Ad41 long fiber protein, Ad41 short fiber protein or any one of Ad41 E3 proteins RL-1 to RL-6 or fragments thereof) will be typically bound to a solid phase and a second molecule, either the second antibody in a sandwich assay, or in a competitive assay, the known amount of antigen, will bear a detectable label or reporter molecule in order to allow visual detection of an antibody-antigen reaction. When two antibodies are employed, as in the sandwich assay, it is only necessary that one of the antibodies be specific for, e.g., Ad41 short or long fiber protein or its antigenic fragments (the tail, the shaft or the knob). The following description will relate to a discussion of a typical forward sandwich assay; however, the general techniques are to be understood as being applicable to any of the contemplated immunoassays.

In the typical forward sandwich assay, a first antibody having specificity for, e.g., Ad41 short or long fiber protein or its antigenic fragments is either covalently or passively bound to a solid surface. The solid surface is typically glass or a polymer, the most commonly used polymers being cellulose, polyacrylamide, nylon, polystyrene, polivinyl chloride or polypropylene. The solid supports may be in the form of tubes, beads, discs or microplates, or any other surface suitable for conducting an immunoassay. The binding processes are well-known in the art and generally consist of cross-linking, covalently binding, or physically adsorbing the molecule to the insoluble carrier. Following binding, the polymer-antibody complex is washed in preparation for the test sample. An aliquot of the sample to be tested is then added to the solid phase complex and incubated at 25°C for a period of time sufficient to allow binding of any subunit present in the antibody. The incubation period will vary, but will generally be in the range of about 2-40 minutes. Following the incubation period, the antibody subunit solid phase is washed and dried and incubated with a second antibody specific for a portion of the hapten. The second antibody is linked to a reporter molecule which is used to indicate the binding of the second antibody to the hapten.

By "reporter molecule", as used in the present specification and claims, is meant a molecule which, by its chemical nature, provides an analytically identifiable signal which allows the detection of antigen-bound antibody. Detection may be either qualitative or quantitative. The most commonly used reporter molecules in this type of assay are either enzymes, fluorophores or radionucleotide containing molecules.

In the case of an enzymic immunoassay (EIA), an enzyme is conjugated to the second antibody, generally by means of glutaraldehyde or periodate. As will be readily recognized, however, a wide variety of different conjugation techniques exist, which are readily available to the skilled artisan. Commonly used enzymes include horseradish peroxidase, glucose oxidase, beta-galactosidase and alkaline phosphates, among others. The substrates to be used with the specific enzymes are generally chosen for the production, upon hydrolysis by the corresponding enzyme, of a detectable color change. For example, p-nitrophenyl phosphate is suitable for use with alkaline phosphatase conjugates; and for peroxidase conjugates, 1,2-phenylenediamine, 5-aminosalicyclic acid, or tolidine are commonly used. It is also possible to employ fluorogenic substrates, which yield a fluorescent product rather than the chromogenic substrates noted above.

In all cases, the enzyme-labeled antibody is added to the first antibody hapten complex, allowed to bind, and then excess reagent is washed away. A solution containing the appropriate substrate is then added to the ternary complex of antibody-antigen-antibody. The substrate will react with the enzyme linked to the second antibody, giving a qualitative visual signal, which may be further quantitated, usually spectrophotometrically, to give an indication of the amount of hapten which was present in the sample.

Alternately, fluorescent compounds, such as fluorescein and rhodamine, may be chemically coupled to antibodies without altering their binding capacity. When activated by illumination with light of a particular

wavelength, the fluorochrome-labeled antibody absorbs the light energy, inducing a state of excitability in the molecule, followed by emission of the light at a characteristic color visually detectable with a light microscope. As in the EIA the fluorescent labeled antibody is allowed to bind to the first antibody-hapten complex. After washing off the unbound reagent, the remaining ternary complex is then exposed to the light of the appropriate wavelength, the fluorescence observed inicates the presence of the hapten of interest. Immunofluorescence and EIA techniques are both very well established in the art and are particularly preferred for the present method. However, other report molecules, such as radioisotope, chemiluminescent of bioluminescent molecules, may also be employed. It will be readily apparent to the skilled technician how to vary the procedure to suit the required purpose. It will also be apparent that the foregoing can be used to detect directly or indirectly (i.e., via antibodies) Type F adenoviruses.

In a preferred embodiment, the present invention also contemplates the use of the Ad41 E3 proteins RL-1 to RL-6 and Ad41 short fiber protein knob and Ad41 long fiber protein knob in enzyme immunoassays for selective detection of human enteric adenoviruses and in particular Ad41 and Ad40 in the stool of patients with gastroenteritis. EIA can give a clear, rapid result in about 2 hours and can therefore be more convenient and efficient and less expensive than a DNA probe test.

The present invention further contemplates an ELISA (enzyme-linked immunoabsorbent assay) test for the presence of antibodies to Ad41 long or short fiber protein or Ad41 E3 proteins RL-1 to RL-6 in serum or other specimens, such as saliva or the duodenal fluid from patients with gastroenteritis. The Ad41 long or short fiber protein "knob" of the present invention can be used, for example, to coat microtiter plates.

The present invention also contemplates the use of recombinant DNA molecules which contain at least one of the following genes: Ad41 long fiber protein gene, Ad41 short fiber protein gene, Ad41 E3 region gene encoding for proteins RL-1, RL-2, RL-3, RL-4, RL-5 or RL-6. The present invention contemplates using these recombinant DNA molecules in the development of diagnostic assays for Ad41. In another embodiment, the present invention contemplates the use of recombinant DNA molecules or derivatives thereof as described above, to generate antibodies useful in diagnostic and therapeutic techniques.

Another aspect of the present invention is the employment of the genetic information contained in the DNA of the Ad41 long fiber protein gene, the Ad41 short fiber protein gene and the Ad41 E3 gene. As defined herein, DNA is referred to as the genetic component of the virus (i.e., double-stranded DNA). Said DNA can be inserted in recombinant expression molecules such that, for example, the Ad41 long fiber protein gene encoded thereon is transcribed and the product can then be obtained. Such products can then be used as antigenic components to generate, for example, antibodies. The present invention contemplates the

transformatian of a host cell or organism with dsDNA of Fig. 1 (Ad41 long fiber protein gene) and/or Fig. 2 (Ad41 short fiber protein gene) and/or Fig. 4 (Ad41 E3 gene) which is capable of producing Ad41 (long or short) fiber protein or Ad41 E3 (RL-1 to RL-6) proteins wherein the host cell or organism is a bacterium (e.g., E. coli), yeast, insect cell or a mammalian cell.

The present invention also relates to DNA described above which can be used to generate probe nucleic acids for hybridization to homologous Ad41 or Ad40 DNA sequences, utilizing at least one of the following Ad41 genes: Ad41 long fiber protein gene, Ad41 short fiber protein gene or Ad41 E3 gene encoding the RL-1 to RL-6 Ad41 proteins.

Another aspect of this invention relates to a recombinant nucleic acid or an isolated nucleic acid molecule, said molecule defined herein to be dsDNA or recombinant DNA encoding Ad41 short fiber protein, Ad41 long fiber protein, or E3 proteins RL-1 to R-6, or parts thereof. In one embodiment the recombinant nucleic acid molecule is complementary DNA (cDNA). It is considered within the scope of the present invention to include the cDNA molecule encoding the above-identified Ad41 proteins, or to regions or parts thereof including any base deletion, insertion or substitution or any other alteration with respect to nucleotide sequence or chemical composition (e.g. methylation and glycosylation). Additionally, the present invention is directed to restriction fragments and synthetic fragments from a nucleic acid encoding the above-identified Ad41 proteins. Moreover, another embodiment of the this invention is directed to the genomic Ad41 long fiber protein gene, Ad41

short fiber protein gene or E3 gene, which may include recombinant clones like cosmids encoding the entire gene or subclones encoding any region of the above-identified genes. Recombinant DNA encoding such subregions of the gene are useful as hybridization probes to detect the presence of the above-identified genes.

Methods considered useful in obtaining recombinant Ad41 cDNA are contained in Maniatis, et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York; (2d Ed. 1989), for example, or any of the myriads of laboratory manuals on recombinant DNA technology which are widely available. Maniatis, et al. further discloses how to obtain deletions and insertions by site-directed mutagenesis, and subsequent selection of mutants for activity.

In a preferred embodiment, the present invention provides a dsDNA or recombinant DNA or cDNA having a nucleotide sequence encoding the Ad41 long fiber protein gene, as shown in Fig. 1. This sequence encodes the 60.6 kd Ad41 long fiber protein having the amino acid sequence shown in Fig. 1.

The present invention further provides a dsDNA or recombinant DNA or cDNA having a nucleotide sequence encoding the Ad41 short fiber as shown in Fig. 2, wherein this sequence encodes a 41.4 kd Ad41 short fiber protein having an amino acid sequence as shown in Fig. 3.

The present invention additionally provides a dsDNA or recombinant DNA or cDNA having a nucleotide sequence which encodes for the E3 region of Ad41 as shown in Fig. 4 wherein this region encodes six E3 proteins, RL-1 to RL-6. The E3 DNA sequence, from base 683 to base 1204, encodes RL-1, a

19.4 kd protein having an amino acid sequence as shown in Fig. 5. The E3 DNA sequence from base 1207 to base 2037 encodes RL-2, a 31.6 kd protein having an amino acid sequence as shown in Fig. 6. The E3 DNA sequence from base 1730 to base 1909 encodes RL-3, a 6.7 kd protein having an amino acid sequence as shown in Fig. 7. The E3 DNA sequence from base 2056 to base 2328 encodes RL-4, a 10.1 kd protein having an amino acid sequence as shown in Fig. 8 The E3 DNA sequence from base 2325 to base 2648 encodes RL-5, a 12.3 kd protein having an amino acid sequence as shown in Fig. 9. The E3 DNA sequence from base 2641 to base 3009 encodes RL-6, a 14.0 kd protein having an amino acid sequence as shown in Fig. 10.

The present invention further contemplates the preparation and use of a vaccine composition for the treatment of human adenovirus type 41 and related adenoviruses, including Ad40. The preparation of said vaccine is accomplished by utilization of at least one of the following adenovirus type 41 proteins: Ad41 short fiber protein, Ad41 long fiber protein, and E3 proteins RL-1 through RL-6. This is done by genetic engineering of at least one of the above-identified proteins and expressing at least one of these proteins in suitable vector/host cell systems such as bacteria, yeast or any other suitable vector/host system. In a further preferred embodiment, the vaccine of the present invention contemplates the use of cloned Ad41 long fiber protein "knob" or short fiber protein "knob" as an immunizing agent.

Previously used vaccines have generally comprised (I) an attenuated live virus type of vaccine in which the virus has been rendered avirulent but not killed by some form

of genetic attenuation; or (II) specific viral components isolated and purified from the virus and inactivated by formalin or some other chemical or physical treatment. The present invention contemplates conventional Type II vaccines, wherein the specific viral components isolated and purified from the virus and inactivated by formalin or other treatments are contemplated to be at least one of Ad41 short fiber protein, AD41 long fiber protein, E3 Rl-1, RL-2, RL-3, RL-4, RL-5 or RL-6 protein. In addition, with respect to Ad41 long and short fiber protein "viral component" also contemplates at least one of the tail, shaft or knob of these proteins. The present invention also contemplates the preparation of recombinant Ad41 proteins for use in a vaccine against Ad41 and Ad40.

In another embodiment, the present invention is directed to a Type II vaccine which is a combination of inactivated Ad41 and at least one of recombinant long and short Ad41 protein fibers and Ad41 E3 proteins RL-1 to RL-6.

By vaccine is meant an agent used to stimulate the immune system of a living organism so that protection against future harm is provided. Administration of a vaccine contemplated by the present invention to the patient (or animal) may be by any known or standard techniques. These include oral ingestion, intestinal intubation, or broncho-nasal spraying. Other methods of administration, such as intravenous injection, that allow the carrier microbe to reach the human or animal's bloodstream may be acceptable when the carrier microbe is unable to reproduce.

Recombinant DNA techniques for the preparation of recombinant Ad41 proteins for use in the preparation of vaccines are sufficiently well known and widespread so as to be considered routine. In very general and broad terms, a method for use herein cosists of transferring the genetic material, or more usually part of the genetic material, of one organism into a second organism so that the transferred genetic material becomes a permanent part of (recombines with) the genetic material of the oganisms to which it is transferred. This usually consists of first obtaining a small piece of DNA from the parent organism either from a plasmid or a parent chromosome. A plasmid (also called an extrachromosomal element) is a hereditary unit that is physically separated from the chromosome of the cell. The DNA may be of any size and is often obtained by the action of a restriction endonuclease enzyme which acts to split DNA molecules at specific base-pair sites. In the present invention an Ad41 long fiber protein gene can be obtained which is a 1.9 kb SmaI-EcoRI DNA fragment or an Ad41 short fiber protein gene which is an EcoRV-AccI DNA fragment or an Ad41 E3 sequence which is an EcoRI-EspI DNA fragment. The DNA pieces of the Ad41 protein gene may be transferred into a host cell by various means such as transformation (uptake of naked DNA from the external environment, which can be artificially induced by the presence of various chemical agents, such as calcium ions). Other methods such as transduction are also suitable, wherein the DNA is packaged within a phage such as the co-called cosmid vector. Once the parent DNA is in the carrier cell, it may continue to exist as a separate piece (generally true of complete transmitted plasmids) or it may insert into the host cell chromosome and be reproduced with the chromosome during cell division.

Transferring genetic materials is relatively straightforward. Any method capable of producing recombinant organisms comprising genes from pathogenic organisms that are expressed in avirulent microbes will suffice. The techniques of DNA isolation, gene cloning, and related techniques are disclosed in great detail in, for example, Recombinant DNA, Methods of Enzymology, Volume 68, Ray Wu, ed., Academic Press (1979), and Maniatiis, T., et al., Molecular Cloning, Cold Spring Harbor Laboratories (1982), which are herein incorprated by references and are applicable to the Ad41 protein gene of the present invention.

Vaccines of the present invention may be administered either as a liquid or in enteric-coated capsules.Such preparations are resistant to acid and enzymes in the stomach of the inoculated animal while dissolving in the intestines. Various enteric-coatings are known in the art, for example, as disclosed in U.S. Patent Nos.3,241,520 and 3,253,944 and are commercially available. A method suitable for preparation of enteric-coated capsules is described in U.S. Patent No. 4,152,415, which is herein incorporated by reference, and can be easily modified to provide capsules containing the carrier microbes of the present invention.

Vaccines of the present invention may be administered orally in enteric-coated capsules as described above or may be administered parenterally (e.g., by intramuscular, subcutaneous, or intravenous injection). The amount required will vary with the antigenicity of the gene product and need only be an amount sufficient to induce an immune response typical of existing vaccines. Routine

experimentation will easily establish the required amount. Typical initial dosages of vaccine could be about 0.001-100 mg antigen/kg body weight, with increasing amounts or multiple dosages used as needed to provide the desired level of protection.

The pharmaceutical carrier in which the vaccine is suspended or dissolved may be any solvent or solid that is non-toxic to the inoculated animal and compatible with the carrier organism or antigenic gene product. Suitable pharmaceutical carriers include liquid carriers, such as normal saline and other non-toxic salts at or near physiological concentrations, and solid carriers, such as talc or sucrose. Adjuvants, such as Freund's adjuvant, complete or incomplete may be added to enhance the antigenicity via the bronchial tubes, the vaccine is suitably present in the form of an aerosol. Booster immunizations may be repeated numerous times with beneficial results.

In a preferred embodiment, the present invention contemplates a vaccine specific to Ad41 long fiber protein or at least one of its active fragments, e.g., the tail, the shaft or the knob of the long fiber protein, a vaccine specific to Ad41 short fiber protein or at least one of its active fragments, or a vaccine specific to at least one of the proteins of the Ad41 E3 region, RL-1 to RL-6.

A number of viral polypeptide preparations derived from viral coats or envelopes have been suggested as possible active components for vaccine compositions. For example, U.S. Patent No. 4,470,967 describes vaccine preparations which are made by complexing viral polypeptide with a lectin, the latter element acting as adjuvant. A number of

references, e.g., 4,344,935 or 4,356,169 or Morein, et al., J. Gen. Virol., 64: 1557-1569, 1983, utilize a method of preparation of parainfluenza glycoprotein compositions in which the viral glycoprotein HN and F are solubilized with a detergent, to extract them from the viral envelope, followed by some method of phase separation in order to remove the detergent and lipids. The latter procedures produce a glycoprotein subunit which is not only detergent free, but also lipid free. The latter type of highly purified glycoprotein is considered the preferred type of active agent for potential use of commercial vaccine.

In another aspect, the present invention relates to a method of treating infectious diseases caused by Ad41 and other related adenoviruses such as Ad40.

The subject invention also encompasses antibodies, either monoclonal or polyclonal, which are useful in the therapeutic control of infection by adenoviruses and in particuliar, Ad41 or Ad40. Said antibodies can be prepared as described above and by injecting mammalian species, e.g., human, horse, rabbit, sheep, mice, etc. with inactivated virus or derivatives thereof (i.e., the tail, shaft or knob) and then purifying said antibodies employing the detection systems contemplated and described herein.

In another embodiment, the present invention relates to the development of specific human or other eukaryotic (e.g., yeast, baculovirus, or Chinese hamster cells) polyclonal or monoclonal antibodies, as well as human-mouse chimeric polyclonal or monoclonal antibodies for administration in passive immunization against human adenoviruses, and in particular, Ad41 and Ad40. Immunization

refers to the process of inducing a continuing high antibody level in an organism i.e., in humans, which is directed against an antigen to which the organism has been previously exposed.

Passive immunization, as defined herein, refers to resistance (e.g., temporary or sustained protection against infection) based on giving preformed antibodies to a patient from an in vivo or in vitro source. The main advantage of passive immunization is the prompt availability of large amounts of antibodies against human adenoviruses as described in the above embodiment of the present invention.

A chimeric antibody, as defined herein, is an antibody molecule made by recombinant DNA technology involving immunoglobulin genes of two different species. The human-mouse chimeric antibody is produced by combining the Fab portion of the mouse immunoglobulin gene and the Fc portion of the human immunoglobulin gene by recombinant DNA technique. The prodution of human-mouse chimeric antibodies is advantageous since large amounts of antibodies can be produced by this system and human-mouse chimeric antibodies can be recognized by cells of the human immune system whereas non-chimeric antibodies would not be recognized as easily by cells (e.g., phagocytic) of the human immune svstem. The chimeric antibodies can be produced in large amounts in the mouse system and can recognize human adenoviruses as contemplated in the present invention. Human-mouse immunoglobulins have also been found to make large amounts of antibodies in yeast and this system is also contemplated herein. The following references discuss the methodologies for producing such antibodies and are incorporated herein by reference: Morrison, et al., P.N.A.S., 81:6851 (1984); Horowitz, et al., P.N.A.S., 85:8678 (1988); and Tao, et al., J. Immunol., 143:2595 (1989).

The present invention also provides a kit for production of recombinant viral components of at least one of the above-identified Ad41 genes, to produce a vaccine to Ad41 or related viruses such as Ad40.

The present invention further contemplates the use of probes to detect hybridization, cellular DNA from infected tissue (e.g.biopsy material) carrying intergrated structural Ad41 DNA (i.e., of the Ad41 long or short fiber protein gene or Ad41 E3 gene). The probe can be DNA, cDNA, recombinant DNA or RNA. The present invention further contemplates a kit for detection of viral components of Ad41 or Ad40.

In one particular embodiment of the present invention, patient specimens (tissue or tissue extracts) containing biopsy material are smeared onto a standard microscope slide, then fixed with an appropriate fixative. The DNA or RNA probe, which has been labeled (e.g. with biotin-avidin-enzyme) is added. The slide is then placed onto a heating block for one or two minutes to allow both the probe and the target nucleic acids to be separated from their complementary strand (if double stranded). Non-hybridized probe DNA or RNA is removed by gentle washing. After a suitable detection complex is added, hybridization is detected with a light microscope following formation of a colored compound. Alternatively, the probe nucleic acid is labeled with a radioactive isotope and tissue to be tested lysed and their DNA fixed to, for example, nitrocellulose paper. Hybridization and DNA/RNA detection systems are well known in the art.

In a further embodiment, the present invention also relates to a kit for the detection of Ad41 long and/or short fiber protein and its active fragments and fiber protein of related adenoviruses and/or Ad41 E3 region proteins, the kit being compartmentalized to receive a first container adapted

to contain an antibody having specificity for Ad41 long and/or short fiber protein or fragments thereof or Ad41 E3 region proteins, and a second container containing an antibody specific for first antibody and being labeled with a reporter molecule capable of giving a detectable signal. If the reporter molecule is an enzyme, then a third container, containing a substrate for said enzyme is provided.

In another embodiment, the present invention contemplates pharmaceutical compositions containing at least one of the above-identified Ad41 proteins, or derivatives thereof, for treatment of Ad41 or related viruses such as Ad40. The dosage effective amount of such compounds is from about 10 mg to about 100 mg per kg body weight.

The DNA sequence comprising the full-lenght, 60.6 kd Ad41 (Tak) long fiber protein has been deposited with the European Molecular Biology Laboratory (EMBL) database and accorded the accession number X16583.

The DNA sequence comprising the full-length 41.4 kd Ad41 short fiber protein has been deposited with the EMBL database and accorded the accession number X17016. The Ad41 E3 DNA sequence has been deposited with the GenBank database an accorded the accession number M33160.

EXAMPLES

1. Cells and virus

Monolayer cultures of HEp-2, HeLa, Human Intestine (HI407), and Graham-293 cell lines were grown in Dulbecco's modification of Eagle minimal essential medium containing 10% fetal bovine serum (FBS). 293 cells were obtained from Flow Laboratories as well as ATCC; all other cell lines were from ATCC. The adenovirus type 41 (Ad41) strain Tak (prototype strain 73-3544 = ATCC #VR-930) used was provided by Dr. Jan C. de Jong, Bilthoven, The Netherlands,

and originally passaged by him in HeLa (p1), Hep-2 (p4) and HeLa (p4). Detailed methods for growth and analysis of Ad41 were performed as described in Pieniazek et. al, Virology, 174: 239-249 (1990) .

2. Isolation of viral DNA

A modification of the method of Hirt, J. Mol. Biol., 26: 365-369 (1967) was used. Monolayers of cells, grown in 25 cm2 flasks, are inoculated with the virus. After 2 hours the solution was discarded and medium containing 5% FBS was added. The cultures were incubated at 37° C for up to 15 days or until maximal CPE could be observed. The cells to be analyzed were scraped into the culture fluid and centrifuged at 1000 x g for 5 min. The pellet was suspended in 0.5 ml of 1 x SSPE buffer, pH 7.4, per flask. EDTA and SDS were added to the final concentration of 50 mM and 1%, respectively. The lysate was allowed to stand 20 min. at room temperature, then NaCl was added to 1.0 M and the sample was incubated at 4° C for at least 1 hr. The high-molecular weight DNA and cell debris was pelleted by spinning the lysate for 15 min. in an Eppendorf centrifuge. T1 RNase was added to the clarified supernatant to a final concentration of 25 ug/ml. After incubation for 30 min. at 37° C proteinase K (Boehringer-Mannheim) was added to 200 um/ml and the sample was further incubated for 30 min. as above. The proteins were removed by one extraction with saturated phenol and one by phenol/chloroform mixture (1:1 v/v) according to the method of Maniatis et al., Molecular Cloning: A Lab Manual, Cold Spring Harbor, NY (1982). DNA was precipitated with 3 volumes of ethanol. Nucleic acid, prepared from one culture flask was suspended in 50 ul of TE buffer (10 mm Tris-HCl, 1 mM EDTA, pH 7.5) and stored at 4° C.

3. Cloning of Ad41 EcoRI band B.

Restriction enzyme EcoRI was purchased from BRL and is used according to manufacturer's specifications. Briefly, 3 ul of sample was digested at 37° C with 5 units of enzyme in a final volume of 10 ul. Nucleic acid fragments were separated by electrophoresis on 1% agarose gels (BioRad) and the EcoRI band was identified by ethidium bromide staining. An agarose fragment containing this band was excised from the gel and the DNA was recovered using the GENECLEAN kit (Bio 101, La Jolla, CA.). This isolated DNA fragment was mixed with EcoR-digested plasmid pBluescipt II SK(+) (Stratagene, La Jolla, CA.) and treated with phage T4 DNA ligase (BRL). Next, competent cells of E. coli strain XL-1 Blue (Stratagene) were transformed with this ligation mixture and a clone containing Ad41 EcoRI band B was selected by estimating the size of the insert and restriction enzyme mapping.

4. DNA Sequencing

Preliminary sequencing was accomplished using the method Deininger, Analyt. Biochem., 135: 247-263 (1983). Ad41 EcoRI band B was isolated from an agarose gel as above and sheered by sonication. The ends of the sheered fragments were then filled with T4 DNA polymerase and the fragments were cloned into the SmaI site of the M13mp18 phage vector. Individual M13 clones were sequenced using the Sequenase kit from USB (Cleveland, OH). DNA sequences were analyzed using the IBI/Pustell software package from IBI (New Haven, CT) and their Gel Reader sonic digitizer.

After locating the start and end of the fiber gene by homology to the published Ad5 fiber sequence (Chroboczek and Jacrot, Virology, 161: 549-554, 1987), Ad41 long fiber gene was sequenced using a modified approach. Custom

oligonucleotide primers were used in a double-stranded DNA sequencing protocol according to the Sequenase Version 2.0 manual (in the Sequenase kit from USB, Clevelans, OH). The complete sequence of the SmaI - EcoRI fragment (map position 86.4% to 92%), shown in Fig. 1, was assemble from fragment obtained by sequencing both strands including sequencing in the presence of dITP to resolve problems with compressions of the DNA.

The same method as described above was utilized for sequencing the Ad41 short fiber gene, and the complete sequence of the EcoRv-AccI fragment (map position 83.1% to 87.1%) is shown in Fig. 2. The Ad41 E3 region DNA was also sequenced in similar fashion, and the complete sequence of this EcoRT-EspI fragment (map position 74% to 83.9%) is shown in Fig. 4.

The protein coding regions of E3 DNA, short fiber DNA and long fiber DNA of human adenovirus type 41 Tak, are shown by the proteins RL-1 to RL-6, short fiber protein and long fiber protein as illustrated in the map of Fig. 11.

WE CLAIM:

1. An isolated nucleic acid encoding a protein selected from human adenovirus type 41 Tak long fiber protein, short fiber protein, E3 RL-1 protein, E3 RL-2 protein, E3 RL-3 protein, E3 RL-4 protein, E3 RL-5 protein or E3 RL-6 protein.

2. The nucleic acid of Claim 1 wherein said nucleic acid is DNA, cDna, recombinant DNA or RNA.

3. The nucleic acid according to Claim 1 or 2 having a nucleotide sequence of the human adenovirus Type 41 Tak long fiber protein gene and which comprises:

ATG AAA CGA GCC AGA CTT GAA GAT GAC TTC AAC CCC
TAC TTT GCT CGG TCT GAA CTT CTA CTG AAG TTG GGG

GTC TAC CCT TAC GAA CAC TAC AAT CCC CTT GAC ATC CCA TTT ATT ACA CCC
CAG ATG GGA ATG CTT GTG ATG TTA GGG GAA CTG TAG GGT AAA TAA TGT GGG

CCG TTT GCC TCC TCC AAC GGC TTG CAA GAA AAA CCA CCG GGA GTC CTC AGC
GGC AAA CGG AGG AGG TTG CCG AAC GTT CTT TTT GGT GGC CCT CAG GAG TCG

CTG AAA TAC ACT GAT CCA CTT ACA ACC AAA AAC GGG GCT TTA ACC TTA AAA
GAC TTT ATG TGA CTA GAA GTA TGT TGG TTT TTG CCC CGA AAT TGG AAT TTT

CTG GGC ACG GGA CTA AAC ATT GAT GAA AAT GGA GAT CTT TCT TCA GAT GCT
GAC CCG TGC CCT GAT TTG TAA CTA CTT TTA CCT CTA GAA AGA AGT CTA CGA

AGC GTG GAA GTT AGC GCC CCT ATT ACT AAA ACC AAC AAA ATC GTA GGT TTA
TCG CAC CTT CAA TCG CGG GGA TAA TGA TTT TGG TTG TTT TAG CAT CCA AAT

AAT TAC ACT AAA CCT CTC GCC CTG CGA AGT AAC GCG CTC ACT CTT TCT TAC
TTA ATG TGA TTT GGA GAG CGG GAC GCT TCA TTG CGC GAG TGA GAA AGA ATG

AAC GCA CCC TTA ACC GTA GTA AAT AAC AAT TTA GCT TTA AAT ATC TCA CAA
TTG CGT GGG AAT TTG CAT CAT TTA TTG TTA AAT CGA AAT TTA TAG AGT GTT

CCT GTC ACT GTT AAT GCA AAC AAC GAA CTT TCT CTC TTA ATA GAC GCC CCA
GGA CAG TGA CAA TTA CGT TTG TTG CTT GAA AGA GAG AAT TAT CTG CGG GGT

```
1   CTT AAT GCT GAC ACG GGC ACT CTT CGC CTT CAA AGT GCT GCA CCT CTT GGA
    GAA TTA CGA CTG TGC CCG TGA GAA GCG GAA GTT TCA CGA CGT GGA GAA CCT

    CTA GTG GAC AAA ACA CTA AAA GTT TTG TTT TCT AGC CCC CTC TAT CTA GAT
5   GAT CAC CTG TTT TGT GAT TTT CAA AAC AAA AGA TCG GGG GAG ATA GAT CTA

    AAT AAC TTT CTT ACA CTA GCC ATT GAA CGC CCG CTA GCT CTA TCC AGT AGC
    TTA TTG AAA GAA TGT GAT CGG TAA CTT GCG GGC GAT CGA GAT AGG TCA TCG

10  AGA GCA GTG ACC CTT AAG TAT TCA CCA CCT TTA AAA ATA GAA AAC GAA AAC
    TCT CGT CAC TGG GAA TTC ATA AGT GGT GGA AAT TTT TAT CTT TTG CTT TTG

    TTA ACC CTA AGC ACA GGC GGG CCT TTT ACT GTA AGC GGG GGA AAT CTA AAC
    AAT TGG GAT TCG TGT CCG CCC GGA AAA TGA CAT TCG CCC CCT TTA GAT TTG
15
    TTA ACA ACA TCG GCA CCT CTC TCC GTG CAA AAC AAC TCT CTC TCC TTA GTC
    AAT TGT TGT AGC CGT GGA GAG AGG CAC GTT TTG TTG AGA GAG AGG AAT CAG

    ATT ACT TCT CCT TTA AAA GTT ATT AAT TCT ATG TTA GCC GTT GGG GTT AAC
20  TAA TGA AGA GGA AAT TTT CAA TAA TTA AGA TAC AAT CGG CAA CCC CAA TTG

    CCG CCT TTT ACC ATC ACT GAC TCT GGA TTA GCT ATG GAC TTA GGA GAC GGT
    GGC GGA AAA TGG TAG TGA CTG AGA CCT AAT CGA TAC CTG AAT CCT CTG CCA

25  CTT GCA CTA GGT GGC TCT AAG TTA ATA ATC AAT CTT GGT CCA GGT TTA CAA
    GAA CGT GAT CCA CCG AGA TTC AAT TAT TAG TTA GAA CCA GGT CCA AAT GTT

    ATG TCT AAT GGA GCT ATT ACT TTA GCA CTA GAT GCA GCG CTG CCT TTG CAA
    TAC AGA TTA CCT CGA TAA TGA AAT CGT GAT CTA CGT CGC GAC GGA AAC GTT
30
    TAT AGA GAC AAC CAA CTT CAA CTC AGA ATT GGC TCA ACA TCT GGC TTA ATT
    ATA TCT CTG TTG GTT GAA GTT GAG TCT TAA CCG AGT TGT AGA CCG AAT TAA

    ATG AGC GGA GTA ACA CAA ACA TTA AAC GTC AAT GCC AAT ACC GGC AAA GGT
35  TAC TCG CCT CAT TGT GTT TGT AAT TTG CAG TTA CGG TTA TGG CCG TTT CCA

    CTT GCT GTT GAA AAC AAC TCA CTA GTT GTT AAG CTT GGG AAC GGT CTT CGC
    GAA CGA CAA CTT TTG TTG AGT GAT CAA CAA TTC GAA CCC TTG CCA GAA GCG
```

```
1   TTT GAT AGC TGG GGA AGC ATA ACT GTC TCG CCT ACT ACC ACT ACC CCT ACC
    AAA CTA TCG ACC CCT TCG TAT TGA CAG AGC GGA TGA TGG TGA TGG GGA TGG

    ACC CTA TGG ACC ACC GCA GAC CCA TCA CCT AAC GCC ACT TTT TAT GAA TCA
5   TGG GAT ACC TGG TGG CGT CTG GGT AGT GGA TTG CGG TGA AAA ATA CTT AGT

    CTA GAC GCC AAA GTG TGG CTA GTT TTA GTA AAA TGC AAC GGC ATG GTT AAC
    GAT CTG CGG TTT CAC ACC GAT CAA AAT CAT TTT ACG TTG CCG TAC CAA TTG

10  GGG ACC ATA TCC ATT AAA GCT CAG AAA GGC ATT TTA CTT AGA CCT ACA GCT
    CCC TGG TAT AGG TAA TTT CGA GTC TTT CCG TAA AAT GAA TCT GGA TGT CGA

    AGT TTT ATT TCC TTT GTC ATG TAT TTC TAC AGC GAT GGA ACA TGG AGA AAA
    TCA AAA TAA AGG AAA CAG TAC ATA AAG ATG TCG CTA CCT TGT ACC TCT TTT
15
    AAC TAT CCC GTG TTT GAC AAC GAA GGG ATA CTA GCA AAC AGT GCC ACG TGG
    TTG ATA GGG CAC AAA CTG TTG CTT CCC TAT GAT CGT TTG TCA CGG TGC ACC

    GGT TAT CGA CAA GGA CAG TCT GCC AAC ACT AAC GTT TCT AAT GCT GTA GAA
20  CCA ATA GCT GTT CCT GTC AGA CGG TTG TGA TTG CAA AGA TTA CGA CAT CTT

    TTT ATG CCT AGC TCT AAA AGA TAT CCC AAT CAA AAA GGT TCT GAA GTT CAG
    AAA TAC GGA TCG AGA TTT TCT ATA GGG TTA GTT TTT CCA AGA CTT CAA GTC

25  AAC ATG GCT CTT ACC TAC ACT TTT TTG CAA GGT GAT CCT AAC ATG GCC ATA
    TTG TAC CGA GAA TGG ATG TGA AAA AAC GTT CCA CTA GGA TTG TAC CGG TAT

    TCC TTT CAG AGT ATT TAT AAT CAT GCA TTA GAA GGC TAC TCA TTA AAA TTT
    AGG AAA GTC TCA TAA ATA TTA GTA CGT AAT CTT CCG ATG AGT AAT TTT AAA
30
    ACC TGG CGC GTT CGA AAT AAT GAA CGT TTT GAC ATC CCC TGC TGC TCA TTT
    TGG ACC GCG CAA GCT TTA TTA CTT GCA AAA CTG TAG GGG ACG ACG AGT AAA

    TCT TAT GTA ACA GAA CAA TAA  A
35  AGA ATA CAT TGT CTT GTT ATT  T
```

4. The nucleic acid according to Claims 1 or 2 having a nucleotide sequence of the human adenovirus Type 41 long fiber protein gene which comprises:

CCCGGGCAAC ATGCTCATCC AAATCTCGCC TAACATCACC TTCAGTGTCG TCTACAACGA
GGGCCCGTTG TACGAGTAGG TTTAGAGCGG ATTGTAGTGG AAGTCACAGC AGATGTTGCT

GATAAACAGT GGGTATGCTT TTACTTTTAA ATGGTCAGCC GAACCGGGAA AACCTTTTCA
CTATTTGTCA CCCATACGAA AATGAAATT TACCAGTCGG CTTGGCCCTT TTGGAAAAGT

CCCACCTACC GCTGTATTTT GCTACATAAC TGAACAATAA AATCATTGCA GGCACAATCT
GGGTGGATGG CGACATAAAA CGATGTATTG ACTTGTTATT TTAGTAACGT CCGTGTTAGA

TCGCATTTCT TTTTTTCCAG ATG AAA CGA GCC AGA CTT GAA GAT GAC TTC AAC CCC
AGCGTAAAGA AAAAAAGGTC TAC TTT GCT CGG TCT GAA CTT CTA CTG AAG TTG GGG

GTC TAC CCT TAC GAA CAC TAC AAT CCC CTT GAC ATC CCA TTT ATT ACA CCC
CAG ATG GGA ATG CTT GTG ATG TTA GGG GAA CTG TAG GGT AAA TAA TGT GGG

CCG TTT GCC TCC TCC AAC GGC TTG CAA GAA AAA CCA CCG GGA GTC CTC AGC
GGC AAA CGG AGG AGG TTG CCG AAC GTT CTT TTT GGT GGC CCT CAG GAG TCG

CTG AAA TAC ACT GAT CCA CTT ACA ACC AAA AAC GGG GCT TTA ACC TTA AAA
GAC TTT ATG TGA CTA GGT GAA TGT TGG TTT TTG CCC CGA AAT TGG AAT TTT

CTG GGC ACG GGA CTA AAC ATT GAT GAA AAT GGA GAT CTT TCT TCA GAT GCT
GAC CCG TGC CCT GAT TTG TAA CTA CTT TTA CCT CTA GAA AGA AGT CTA CGA

AGC GTG GAA GTT AGC GCC CCT ATT ACT AAA ACC AAC AAA ATC GTA GGT TTA
TCG CAC CTT CAA TCG CGG GGA TAA TGA TTT TGG TTG TTT TAG CAT CCA AAT

AAT TAC ACT AAA CCT CTC GCC CTG CGA AGT AAC GCG CTC ACT CTT TCT TAC
TTA ATG TGA TTT GGA GAG CGG GAC GCT TCA TTG CGC GAG TGA GAA AGA ATG

AAC GCA CCC TTA AAC GTA GTA AAT AAC AAT TTA GCT TTA AAT ATC TCA CAA
TTG CGT GGG AAT TTG CAT CAT TTA TTG TTA AAT CGA AAT TTA TAG AGT GTT

CCT GTC ACT GTT AAT GCA AAC AAC GAA CTT TCT CTC TTA ATA GAC GCC CCA
GGA CAG TGA CAA TTA CGT TTG TTG CTT GAA AGA GAG AAT TAT CTG CGG GGT

```
1   CTT AAT GCT GAC ACG GGC ACT CTT CGC CTT CAA AGT GCT GCA CCT CTT GGA
    GAA TTA CGA CTG TGC CCG TGA GAA GCG GAA GTT TCA CGA CGT GGA GAA CCT

    CTA GTG GAC AAA ACA CTA AAA GTT TTG TTT TCT AGC CCC CTC TAT CTA GAT
5   GAT CAC CTG TTT TGT GAT TTT CAA AAC AAA AGA TCG GGG GAG ATA GAT CTA

    AAT AAC TTT CTT ACA CTA GCC ATT GAA CGC CCG CTA GTC CTA TCC AGT AGC
    TTA TTG AAA GAA TGT GAT CGG TAA CTT GCG GGC GAT CGA GAT AGG TCA TCG

10  AGA GCA GTG ACC CTT AAG TAT TCA CCA CCT TTA AAA ATA GAA AAC GAA AAC
    TCT CGT CAC TGG GAA TTC ATA AGT GGT GGA AAT TTT TAT CTT TTG CTT TTG

    TTA ACC CTA AGC ACA GGC GGG CCT TTT ACT GTA AGC GGG GGA AAT CTA AAC
    AAT TGG GAT TCG TGT CCG CCC GGA AAA TGA CAT TCG CCC CCT TTA GAT TTG
15
    ATT ACT TCT CCT TTA AAA GTT ATT AAT TCT ATG TTA GCC GTT GGG GTT AAC
    TAA TGA AGA GGA AAT TTT CAA TAA TTA AGA TAC AAT CGG CAA CCC CAA TTG

    CCG CCT TTT ACC ATC ACT GAC TCT GGA TTA GCT ATG GAC TTA GGA GAC GGT
20  GGC GGA AAA TGG TAG TGA CTG AGA CCT AAT CGA TAC CTG AAT CCT CTG CCA

    CTT GCA CTA GGT GGC TCT AAG TTA ATA ATC AAT CTT GGT CCA GGT TTA CAA
    GAA CGT GAT CCA CCG AGA TTC AAT TAT TAG TTA GAA CCA GGT CCA AAT GTT

25  ATG TCT AAT GGA GCT ATT ACT TTA GCA CTA GAT GCA GCG CTG CCT TTG CAA
    TAC AGA TTA CCT CGA TAA TGA AAT CGT GAT CTA CGT CGC GAC GGA AAC GTT

    TAT AGA GAC AAC CAA CTT CAA CTC AGA ATT GGC TCA ACA TCT GGC TTA ATT
    ATA TCT CTG TTG GTT GAA GTT GAG TCT TAA CCG AGT TGT AGA CCG ATT TAA
30
    ATG AGC GGA GTA ACA CAA ACA TTA AAC GTC AAT GCC AAT ACC GGC AAA GGT
    TAC TCG CCT CAT TGT GTT TGT AAT TTG CAG TTA CGG TTA TGG CCG TTT CCA

    CTT GCT GTT GAA AAC AAC TCA CTA GTT GTT AAG CTT GGG AAC GGT CTT CGC
35  GAA CGA CAA CTT TTG TTG AGT GAT CAA CAA TTC GAA CCC TTG CCA GAA GCG

    TTT GAT AGC TGG GGA AGC ATA ACT GTC TCG CCT ACT ACC ACT ACC CCT ACC
    AAA CTA TCG ACC CCT TCG TAT TGA CAG AGC GGA TGA TGG TGA TGG GGA TGG
```

```
1   ACC CTA TGG ACC ACC GCA GAC CCA TCA CCT AAC GCC ACT TTT TAT GAA TCA
    TGG GAT ACC TGG TGG CGT CTG GGT AGT GGA TTG CGG TGA AAA ATA CTT AGT

    CTA GAC GCC AAA GTG TGG CTA GTT TTA GTA AAA TGC AAC GGC ATG GTT AAC
5   GAT CTG CGG TTT CAC ACC GAT CAA AAT CAT TTT ACG TTG CCG TAC CAA TTG

    GGG ACC ATA TCC ATT AAA GCT CAG AAA GGC ATT TTA CTT AGA CCT ACA GCT
    CCC TGG TAT AGG TAA TTT CGA GTC TTT CCG TAA AAT GAA TCT GGA TGT CGA

10  AGT TTT ATT TCC TTT GTC ATG TAT TTC TAC AGC GAT GGA ACA TGG AGA AAA
    TCA AAA TAA AGG AAA CAG TAC ATA AAG ATG TCG CTA CCT TGT ACC TCT TTT

    AAC TAT CCC GTG TTT GAC AAC GAA GGG ATA CTA GCA AAC AGT GCC ACG TGG
    TTG ATA GGG CAC AAA CTG TTG CTT CCC TAT GAT CGT TTG TCA CGG TGC ACC

15
    GGT TAT CGA CAA GGA CAG TCT GCC AAC ACT AAC GTT TCT AAT GCT GTA GAA
    CCA ATA GCT GTT CCT GTC AGA CGG TTG TGA TTG CAA AGA TTA CGA CAT CTT

    TTT ATG CCT AGC TCT AAA AGA TAT CCC AAT CAA AAA GGT TCT GAA GTT CAG
20  AAA TAC GGA TCG AGA TTT TCT ATA GGG TTA GTT TTT CCA AGA CTT CAA GTC

    AAC ATG GCT CTT ACC TAC ACT TTT TTG CAA GGT GAT CCT AAC ATG GCC ATA
    TTG TAC CGA GAA TGG ATG TGA AAA AAC GTT CCA CTA GGA TTG TAC CGG TAT

25  TCC TTT CAG AGT ATT TAT AAT CAT GCA TTA GAA GGC TAC TCA TTA AAA TTT
    AGG AAA GTC TCA TAA ATA TTA GTA CGT AAT CTT CCG ATG AGT AAT TTT AAA

    ACC TGG CGC GTT CGA AAT AAT GAA CGT TTT GAC ATC CCC TGC TGC TCA TTT
    TGG ACC GCG CAA GCT TTA TTA CTT GCA AAA CTG TAG GGG ACG ACG AGT AAA

30
    TCT TAT GTA ACA GAA CAA TAA A ATATTGTTGT TTTTGTTTTT ATAACTTTAT
    AGA ATA CAT TGT CTT GTT ATT T TATAACAACA AAAACAAAAA TATTGAAATA

    TGATACTTTT ACAGAATTC
35  ACTATGAAAA TGTCTTAAG
```

5. The nucleic acid according to Claim 1 or 2 having a nucleotide sequence encoding an amino acid sequence for Ad41 long fiber protein which comprises:

Met Lys Arg Ala Arg Leu Glu Asp Asp Phe Asn Pro
Val Tyr Pro Tyr Glu His Tyr Asn Pro Leu Asp Ile Pro Phe Ile Thr Pro
Pro Phe Ala Ser Ser Asn Gly Leu Gln Glu Lys Pro Pro Gly Val Leu Ser
Leu Gly Thr Gly Leu Asn Ile Asp Glu Asn Gly Asp Leu Ser Ser Asp Ala
Ser Val Glu Val Ser Ala Pro Ile Thr Lys Thr Asn Lys Ile Val Gly Leu
Asn Tyr Thr Lys Pro Leu Ala Leu Arg Ser Asn Ala Leu Thr Leu Ser Tyr
Asn Ala Pro Leu Asn Val Val Asn Asn Asn Leu Ala Leu Asn Ile Ser Gln
Pro Val Thr Val Asn Ala Asn Asn Glu Leu Ser Leu Leu Ile Asp Ala Pro
Leu Asn Ala Asp Thr Gly Thr Leu Arg Leu Gln Ser Ala Ala Pro Leu Gly
Leu Val Asp Lys Thr Leu Lys Val Leu Phe Ser Ser Pro Leu Tyr Leu Asp
Asn Asn Phe Leu Thr Leu Ala Ile Glu Arg Pro Leu Ala Leu Ser Ser Ser
Arg Ala Val Thr Leu Lys Tyr Ser Pro Pro Leu Lys Ile Glu Asn Glu Asn Leu
Thr Leu Ser Thr Gly Gly Pro Phe Thr Val Ser Gly Gly Asn Leu Asn Leu Thr
Thr Ser Ala Pro Leu Ser Val Gln Asn Asn Ser Leu Ser Leu Val Ile Thr Ser
Pro Leu Lys Val Ile Asn Ser Met Leu Ala Val Gly Val Asn Pro Pro Phe Thr
Ile Thr Asp Ser Gly Leu Ala Met Asp Leu Gly Asp Gly Leu Ala Leu Gly Gly
Ser Lys Leu Ile Ile Asn Leu Gly Pro Gly Leu Gln Met Ser Asn Gly Ala Ile
Thr Leu Ala Leu Asp Ala Ala Leu Pro Leu Gln Tyr Arg Asp Asn Gln Leu Gln
Leu Arg Ile Gly Ser Thr Ser Gly Leu Ile Met Ser Gly Val Thr Gln Thr Leu
Asn Val Asn Ala Asn Thr Gly Lys Gly Leu Ala Val Glu Asn Asn Ser Leu Val
Val Lys Leu Gly Asn Gly Leu Arg Phe Asp Ser Trp Gly Ser Ile Thr Val Ser
Pro Thr Thr Thr Thr Pro Thr Thr Leu Trp Thr Thr Ala Asp Pro Ser Pro Asn
Ala Thr Phe Tyr Glu Ser Leu Asp Ala Lys Val Trp Leu Val Leu Val Lys Cys
Asn Gly Met Val Asn Gly Thr Ile Ser Ile Lys Ala Gln Lys Gly Ile Leu Leu
Arg Pro Thr Ala Ser Phe Ile Ser Phe Val Met Tyr Phe Tyr Ser Asp Gly Thr
Trp Arg Lys Asn Tyr Pro Val Phe Asp Asn Glu Gly Ile Leu Ala Asn Ser Ala
Thr Trp Gly Tyr Arg Gln Gly Gln Ser Ala Asn Thr Asn Val Ser Asn Ala Val
Glu Phe Met Pro Ser Ser Lys Arg Tyr Pro Asn Gln Lys Gly Ser Glu Val Gln
Asn Met Ala Leu Thr Tyr Thr Phe Leu Gln Gly Asp Pro Asn Met Ala Ile Ser
Phe Gln Ser Ile Tyr Asn His Ala Leu Glu Gly Tyr Ser Leu Lys Phe Thr Trp
Arg Val Arg Asn Asn Glu Arg Phe Asp Ile Pro Cys Cys Ser Phe Ser Tyr Val
Thr Glu Gln

6. The nucleic acid according to Claim 1 or 2 having a nucleotide sequence of human adenovirus type 41 short fiber protein which comprises:

ATG AAA AGA ACC AGA ATT
TAC TTT TCT TGG TCT TAA

GAA GAC GAC TTC AAC CCC GTC TAC CCC TAT GAC ACC TTC TCA ACT CCC
CTT CTG CTG AAG TTG GGG CAG ATG GGG ATA CTG TGG AAG AGT TGA GGG

AGC ATC CCC TAT GTA GCT CCG CCC TTC GTT TCT TCT GAC GGG TTA CAG
TCG TAG GGG ATA CAT CGA GGC GGG AAG CAA AGA AGA CTG CCC AAT GTC

GAA AAA CCC CCA GGA GTT TTA GCA CTC AAG TAC ACT GAC CCC ATT ACT
CTT TTT GGG GGT CCT CAA AAT CGT GAG TTC ATG TGA CTG GGG TAA TGA

ACC AAT GCT AAG CAT GAG CTT ACT TTA AAA CTT GGA AGC AAC ATA ACT
TGG TTA CGA TTC GTA CTC GAA TGA AAT TTT GAA CCT TCG TTG TAT TGA

TTA GAA AAT GGG TTA CTT TCG GCC ACA GTT CCC ACT GTT TCT CCT CCC
AAT CTT TTA CCC AAT GAA AGC CGG TGT CAA GGG TGA CAA AGA GGA GGG

CTT ACA AAC AGT AAC AAC TCC CTG GGT TTA GCC ACA TCC GCT CCC ATA
GAA TGT TTG TCA TTG TTG AGG GAC CCA AAT CGG TGT AGG CGA GGG TAT

GCT GTA TCA GCT AAC TCT CTC ACA TTG GCC ACC GCC GCA CCA CTG ACA
CGA CAT AGT CGA TTG AGA GAG TGT AAC CGG TGG CGG CGT GGT GAC TGT

GTA AGC AAC AAC CAG CTT AGT ATT AAC GCG GGC AGA GGT TTA GTT ATA
CAT TCG TTG TTG GTC GAA TCA TAA TTG CGC CCG TCT CCA AAT CAA TAT

ACT AAC AAT GCC TTA ACA GTT AAT CCT ACC GGA GCG CTA GGT TTC AAT
TGA TTG TTA CGG AAT TGT CAA TTA GGA TGG CCT CGC GAT CCA AAG TTA

AAC ACA GGA GCT TTA CAA TTA AAT GCT GCA GGA GGA ATG AGA GTG GAC
TTG TGT CCT CGA AAT GTT AAT TTA CGA CGT CCT CCT TAC TCT CAC CTG

GGT GCC AAC TTA ATT CTT CAT GTA GCA TAA CCC TTT GAA GCA ATC AAC
CCA CGG TTG AAT TAA GAA GTA CAT CGT ATA GGG AAA CTT CGT TAG TTG

```
1   CAG CTA ACA CTG CGA TTA GAA AAC GGG TTA GAA GTA ACC AGC GGA GGA
    GTC GAT TGT GAC GCT AAT CTT TTG CCC AAT CTT CAT TGG TCG CCT CCT

    AAG CTT AAC GTT AAG TTG GGA TCA GGC CTC CAA TTT GAC AGT AAC GGA
5   TTC GAA TTG CAA TTC AAC CCT AGT CCG GRG GTT AAA CTG TCA TTG CCT

    CGC ATT GCT ATT AGT AAT AGC AAC CGA ACT CGA AGT GTA CCA TCC CTC
    GCG TAA CGA TAA TCA TTA TCG TTG GCT TGA GCT TCA CAT GGT AGG GAG

10  ACT ACC ATT TGG TCT ATC TCG CCT ACG CCT AAC TGC TCC ATT TAT GAA
    TGA TGG TAA ACC AGA TAG AGC GGA TGC GGA TTG ACG AGG TAA ATA CTT

    ACC CAA GAT GCA AAC CTA TTT CTT TGT CTA ACT AAA AAC GGA GCT CAC
    TGG GTT CTA CGT TTG GAT AAA GAA ACA GAT TGA TTT TTG CCT CGA GTG
15
    GTA TTA GGT ACT ATA ACA ATC AAA GGT CTT AAA GGA GCA CTG CGG GAA
    CAT AAT CCA TGA TAT TGT TAG TTT CCA GAA TTT CCT CGT GAC GCC CTT

    ATG CAC GAT AAC GCT CTA TCT TTA AAA CTT CCC TTT GAC AAT CAG GGA
20  TAC GTG CTA TTG CGA GAT AGA AAT TTT GAA GGG AAA CTG TTA GTC CCT

    AAT TTA CTT AAC TGT GCC TTG GAA TCA TCC ACC TGG CGT TAC CAG GAA
    TTA AAT GAA TTG ACA CGG AAC CTT AGT AGG TGG ACC GCA ATG GTC CTT

25  ACC AAC GCA GTG GCC TCT AAT GCC TTA ACA TTT ATG CCC AAC AGT ACA
    TGG TTG CGT CAC CGG AGA TTA CGG AAT TGT AAA TAC GGG TTG TCA TGT

    GTG TAT CCA CGA AAC AAA ACC GCT CAC CCG GGC AAC ATG CTC ATC CAA
    CAC ATA GGT GCT TTG TTT TGG CGA GTG GGC CCG TTG TAC GAG TAG GTT
30
    ATC TCG CCT AAC ATC ACC TTC AGT GTC GTC TAC AAC GAG ATA AAC AGT
    TAG AGC GGA TTG TAG TGG AAG TCA CAG CAG ATG TTG CTC TAT TTG TCA

    GGG TAT GCT TTT ACT TTT AAA TGG TCA GCC GAA CCG GGA AAA CCT TTT
35  CCC ATA CGA AAA TGA AAA TTT ACC AGT CGG CTT GGC CCT TTT GGA AAA

    CAC CCA CCT ACC GCT GTA TTT TGC TAC ATA ACT GAA CAA TAA
    GTG GGT GGA TGG CGA CAT AAA ACG ATG TAT TGA CTT GTT ATT
```

7. The nucleic acid according to Claim 1 or 2 having a nucleotide sequence of human adenovirus type 41 Tak short fiber protein which comprises:

GATATCAGTT GTTTGTCAAG TTTTTCCAGC AGCACCACCT GCCCTTCCTC CCAACTTTCG
CTATAGTCAA CAAACAGTTC AAAAAGGTCG TCGTGGTGGA CGGGAAGGAG GGTTGAAAGC

TAGGGGATGT GCCAACGGGC AGCAAACTTT CTCCACGTCC TAAAGGGTAT ATCGGTGTTC
ATCCCCTACA CGGTTGCCCG TCGTTTGAAA GAGGTGCAGG ATTTCCCATA TAGCCACAAG

ACCTTTTTAC CCTGACCCAC GATCTTCATC TTGCAG ATG AAA AGA ACC AGA ATT
TGGAAAAATG GGACTGGGTG CTAGAAGTAG AACGTC TAC TTT TCT TGG TCT TAA

GAA GAC GAC TTC AAC CCC GTC TAC CCC TAT GAC ACC TTC TCA ACT CCC
CTT CTG CTG AAG TTG GGG CAG ATG GGG ATA CTG TGG AAG AGT TGA GGG

AGC ATC CCC TAT GTA GCT CCG CCC TTC GTT TCT TCT GAC GGG TTA CAG
TCG TAG GGG ATA CAT CGA GGC GGG AAG CAA AGA AGA CTG CCC AAT GTC

GAA AAA CCC CCA GGA GTT TTA GCA CTC AAG TAC ACT GAC CCC ATT ACT
CTT TTT GGG GGT CCT CAA AAT CGT GAG TTC ATG TGA CTG GGG TAA TGA

ACC AAT GCT AAG CAT GAG CTT ACT TTA AAA CTT GGA AGC AAC ATA ACT
TGG TTA CGA TTC GTA CTC GAA TGA AAT TTT GAA CCT TCG TTG TAT TGA

TTA GAA AAT GGG TTA CTT TCG GCC ACA GTT CCC ACT GTT TCT CCT CCC
AAT CTT TTA CCC AAT GAA AGC CGG TGT CAA GGG TGA CAA AGA GGA GGG

CTT ACA AAC AGT AAC AAC TCC CTG GGT TTA GCC ACA TCC GCT CCC ATA
GAA TGT TTG TCA TTG TTG AGG GAC CCA AAT CGG TGT AGG CGA GGG TAT

GCT GTA TCA GCT AAC TCT CTC ACA TTG GCC ACC GCC GCA CCA CTG ACA
CGA CAT AGT CGA TTG AGA GAG TGT AAC CGG TGG CGG CGT GGT GAC TGT

GTA AGC AAC AAC CAG CTT AGT ATT AAC GCG GGC AGA GGT TTA GTT ATA
CAT TCG TTG TTG GTC GAA TCA TAA TTG CGC CCG TCT CCA AAT CAA TAT

ACT AAC AAT GCC TTA ACA GTT AAT CCT ACC GGA GCG CTA GGT TTC AAT
TGA TTG TTA CGG AAT TGT CAA TTA GGA TGG CCT CGC GAT CCA AAG TTA

```
1   AAC ACA GGA GCT TTA CAA TTA AAT GCT GCA GGA GGA ATG AGA GTG GAC
    TTG TGT CCT CGA AAT GTT AAT TTA CGA CGT CCT CCT TAC TCT CAC CTG

    GGT GCC AAC TTA ATT CTT CAT GTA GCA TAT CCC TTT GAA GCA ATC AAC
5   CCA CGG TTG AAT TAA GAA GTA CAT CGT ATA GGG AAA CTT CGT TAG TTG

    CAG CTA ACA CTG CGA TTA GAA AAC GGG TTA GAA GTA ACC AGC GGA GGA
    GTC GAT TGT GAC GCT AAT CTT TTG CCC AAT CTT CAT TGG TCG CCT CCT

10  AAG CTT AAC GTT AAG TTG GGA TCA GGC CTC CAA TTT GAC AGT AAC GGA
    TTC GAA TTG CAA TTC AAC CCT AGT CCG GAG GTT AAA CTG TCA TTG CCT

    CGC ATT GCT ATT AGT AAT AGC AAC CGA ACT CGA AGT GTA CCA TCC CTC
    GCG TAA CGA TAA TCA TTA TCG TTG GCT TGA GCT TCA CAT GGT AGG GAG

15

    ACT ACC ATT TGG TCT ATC TCG CCT ACG CCT AAC TGC TCC ATT TAT GAA
    TGA TGG TAA ACC AGA TAG AGC GGA TGC GGA TTG ACG AGG TAA ATA CTT

    ACC CAA GAT GCA AAC CTA TTT CTT TGT CTA ACT AAA AAC GGA GCT CAC
20  TGG GTT CTA CGT TTG GAT AAA GAA ACA GAT TGA TTT TTG CCT CGA GTG

    GTA TTA GGT ACT ATA ACA ATC AAA GGT CTT AAA GGA GCA CTG CGG GAA
    CAT AAT CCA TGA TAT TGT TAG TTT CCA GAA TTT CCT CGT GAC GCC CTT

25  ATG CAC GAT AAC GCT CTA TCT TTA AAA CTT CCC TTT GAC AAT CAG GGA
    TAC GTG CTA TTG CGA GAT AGA AAT TTT GAA GGG AAA CTG TTA GTC CCT

    AAT TTA CTT AAC TGT GCC TTG GAA TCA TCC ACC TGG CGT TAC CAG GAA
    TTA AAT GAA TTG ACA CGG AAC CTT AGT AGG TGG ACC GCA ATG GTC CTT

30

    ACC AAC GCA GTG GCC TCT AAT GCC TTA ACA TTT ATG CCC AAC AGT ACA
    TGG TTG CGT CAC CGG AGA TTA CGG AAT TGT AAA TAC GGG TTG TCA TGT

    GTG TAT CCA CGA AAC AAA ACC GCT CAC CCG GGC AAC ATG CTC ATC CAA
35  CAC ATA GGT GCT TTG TTT TGG CGA GTG GGC CCG TTG TAC GAG TAG GTT
```

1 ATC TCG CCT AAC ATC ACC TTC AGT GTC GTC TAC AAC GAG ATA AAC AGT
TAG AGC GGA TTG TAG TGG AAG TCA CAG CAG ATG TTG CTC TAT TTG TCA

GGG TAT GCT TTT ACT TTT AAA TGG TCA GCC GAA CCG GGA AAA CCT TTT
5 CCC ATA CGA AAA TGA AAA·TTT ACC AGT CGG CTT GGC CCT TTT GGA AAA

CAC CCA CCT ACC GCT GTA TTT TGC TAC ATA ACT GAA CAA TAA
GTG GGT GGA TGG CGA CAT AAA ACG ATG TAT TGA CTT GTT ATT

10 AATCATTGCA GGCACAATCT TCGCATTTCT TTTTTTCCAG ATGAAACGAG CCAGACTTGA
TTAGTAACGT CCGTGTTAGA AGCGTAAAGA AAAAAAGGTC TACTTTGCTC GGTCTGAACT
AGATGACTTC AACCCCGTCT AC
TCTACTGAAG TTGGGGCAGA TG

15 8. The nucleic acid according to Claim 1 or 2 having a nucleotide sequence encoding an amino acid sequence for Ad41 short fiber protein which comprises: Met Lys Arg Thr Arg Ile Glu Asp Asp Phe Asn Pro Val Tyr Pro Tyr Asp Thr Phe Ser Thr Pro Ser Ile Pro Tyr Val Ala Pro Pro Phe Val Ser Ser Asp Gly Leu Gln Glu Lys Pro Pro Gly Val Leu Ala Leu Lys Tyr Thr Asp Pro Ile Thr Thr Asn Ala
20 Lys His Glu Leu Thr Leu Lys Leu Gly Ser Asn Ile Thr Leu Glu Asn Gly Leu Leu Ser Ala Thr Val Pro Thr Val Ser Pro Pro Leu Thr Asn Ser Asn Asn Ser Leu Gly Leu Ala Thr Ser Ala Pro Ile Ala Val Ser Ala Asn Ser Leu Thr Leu Ala Thr Ala Ala Pro Leu Thr Val Ser Asn Asn Gln Leu Ser Ile Asn Ala Gly Arg Gly Leu Val Ile Thr Asn Asn Ala Leu Thr Val Asn Pro Thr Gly Ala Leu Gly Phe Asn Asn Thr
25 Gly Ala Leu Gln Leu Asn Ala Ala Gly Gly Met Arg Val Asp Gly Ala Asn Leu Ile Leu His Val Ala Tyr Pro Phe Glu Ala Ile Asn Gln Leu Thr Leu Arg Leu Glu Asn Gly Leu Glu Val Thr Ser Gly Gly Lys Leu Asn Val Lys Leu Gly Ser Gly Leu Gln Phe Asp Ser Asn Gly Arg Ile Ala Ile Ser Asn Ser Asn Arg Thr Arg Ser Val Pro Ser Leu Thr Thr Ile Trp Ser Ile Ser Pro Thr Pro Asn Cys Ser Ile Tyr Glu Thr
30 Gln Asp Ala Asn Leu Phe Leu Cys Leu Thr Lys Asn Gly Ala His Val Leu Gly Thr Ile Thr Ile Lys Gly Leu Lys Gly Ala Leu Arg Glu Met His Asp Asn Ala Leu Ser Leu Lys Leu Pro Phe Asp Asn Gln Gly Asn Leu Leu Asn Cys Ala Leu Glu Ser Ser Thr Trp Arg Tyr Gln Glu Thr Asn Ala Val Ala Ser Asn Ala Leu Thr Phe Met Pro Asn Ser Thr Val Tyr Pro Arg Asn Lys Thr Ala His Pro Gly Asn Met Leu Ile Gln
35 Ile Ser Pro Asn Ile Thr Phe Ser Val Val Tyr Asn Glu Ile Asn Ser Gly Tyr Ala Phe Thr Phe Lys Trp Ser Ala Glu Pro Gly Lys Pro Phe His Pro Pro Thr Ala Val Phe Cys Tyr Ile Thr Glu Gln

9. The nucleic acid according to Claim 1 or 2 encoding the E3 region which encodes RL-1, RL-2, RL-3, RL-4, RL-5, and RL-6 protein of human adenovirus Type 41 having a nucleotide sequence which comprises:

```
         10         20         30         40         50         60
*    *    *    *    *    *    *    *    *    *    *    *
 GAATTCGCGC CACTCGAAAC CAAATTTTGC TGGAGCAAGC TGCCCTGACC TCCACCCCGC
 CTTAAGCGCG GTGAGCTTTG GTTTAAAACG ACCTCGTTCG ACGGGACTGG AGGTGGGGCG
         70         80         90        100        110        120
*    *    *    *    *    *    *    *    *    *    *    *
 GAAGTCAATT GAACCCGCCC AATTGGCCCG CTGCCCAGGT GTATCAGGAA AACCCCGCTC
 CTTCAGTTAA CTTGGGCGGG TTAACCGGGC GACGGGTCCA CATAGTCCTT TTGGGGCGAG
        130        140        150        160        170        180
*    *    *    *    *    *    *    *    *    *    *    *
 CGACCACAGT TCTCCTGCCA CGCGACGCTG AGGCCGAAGT CCAAATGACT AACTCCGGAG
 GCTGGTGTCA AGAGGACGGT GCGCTGCGAC TCCGGCTTCA GGTTTACTGA TTGAGGCCTC
        190        200        210        220        230        240
*    *    *    *    *    *    *    *    *    *    *    *
 CGCAATTAGC GGGCGGATCC AGACACGTCA GGTTCAGAGG TCGGTCCTCG CCCTACTCTC
 GCGTTAATCG CCCGCCTAGG TCTGTGCAGT CCAAGTCTCC AGCCAGGAGC GGGATGAGAG
        250        260        270        280        290        300
*    *    *    *    *    *    *    *    *    *    *    *
 CAGGTCCTAT AAAGAGGCTG ATTATCCGAG GCCGGGGTAT CCAGCTCAAC GACGAAGTGG
 GTCCAGGATA TTTCTCCGAC TAATAGGCTC CGGCCCCATA GGTCGAGTTG CTGCTTCACC
```

```
1          310         320         330         340         350         360
     *     *     *     *     *     *     *     *     *     *     *     *
      TGAGCTCCTT AACCGGTCTC CGACCTGACG GAGTTTTCCA GCTTGGAGGT GCCGGCCGCT
      ACTCGAGGAA TTGGCCAGAG GCTGGACTGC CTCAAAAGGT CGAACCTCCA CGGCCGGCGA
5          370         380         390         400         410         420
     *     *     *     *     *     *     *     *     *     *     *     *
      CCTCCTTCAC-TCCTCGCCAG GCGTACCTGA CACTCCAGAG CTCTTCTTCC-CAGCCTCGCT
      GGAGGAAGTG AGGAGCGGTC CGCATGGACT GTGAGGTCTC GAGAAGAAGG GTCGGAGCGA
               430         440         450         460         470         480
10   *     *     *     *     *     *     *     *     *     *     *     *
      CCGGCGGCAT TGGAACCCTC CAGTTTGTGG AGGAGTTTGT ACCCTCCGTT TACTTCAACC
      GGCCGCCGTA ACCTTGGGAG GTCAAACACC TCCTCAAACA TGGGAGGCAA ATGAAGTTGG
               490         500         510         520         530         540
     *     *     *     *     *     *     *     *     *     *     *     *
15    CATTCTCGGG CGCTCCTGGT CTTTACCCAG ACGACTTCAT CCCAAACTAC GACGCGGTGA
      GTAAGAGCCC GCGAGGACCA GAAATGGGTC TGCTGAAGTA GGGTTTGATG CTGCGCCACT
               550         560         570         580         590         600
     *     *     *     *     *     *     *     *     *     *     *     *
      GCGAATCTGT GGACGGCTAC GACTGAATCC CAATGGTGCG TCCGTGACTG TGTGGCTGCA
20    CGCTTAGACA CCTGCCGATG CTGACTTAGG GTTACCACGC AGGCACTGAC ACACCGACGT
               610         620         630         640         650         660
     *     *     *     *     *     *     *     *     *     *     *     *
      ACATCTACAT CGGCGCCGTA ATCCTTGCTA CTTTGTCTGA AAAGTCTGTG ATTTTTACTT
      TGTAGATGTA GCCGCGGCAT TAGGAACGAT GAAACAGACT TTTCAGACAC TAAAAATGAA
25             670         680         690         700         710         720
     *     *     *     *     *     *     *     *     *     *     *     *
      ACCGCTCCAG CGCTTGGATT ACATGAAGAT CTGTGTTCTT TTTTGTGTGC TAAGTTTAAC
      TGGCGAGGTC GCGAACCTAA TGTACTTCTA GACACAAGAA AAAACACACG ATTCAAATTG
               730         740         750         760         770         780
30   *     *     *     *     *     *     *     *     *     *     *     *
      AAGTAGCCTA AGGACTTCAC CTACAACCGT TGGTTCCTTA CGTCAGCTAC AAGATTCCAC
      TTCATCGGAT TCCTGAAGTG GATGTTGGCA ACCAAGGAAT GCAGTCGATG TTCTAAGGTG
               790         800         810         820         830         840
     *     *     *     *     *     *     *     *     *     *     *     *
35    CAAAGGTACA CACCAAACTC TTTATTTTTC TGAGTCTACC ACTTCTATTG CACTTAACTG
      GTTTCCATGT GTGGTTTGAG AAATAAAAAG ACTCAGATGG TGAAGATAAC GTGAATTGAC
```

```
1          850         860         870         880         890         900
       *     *     *     *     *     *     *     *     *     *     *     *
        TTCTTGTCGT AACCAACTCG TTCAGTGGCG CGCTAACAGA CAATTTTGCA AACTATTTTG
        AAGAACAGCA TTGGTTGAGC AAGTCACCGC GCGATTGTCT GTTAAAACGT TTGATAAAAC
5          910         920         930         940         950         960
       *     *     *     *     *     *     *     *     *     *     *     *
        GGACGCTCTT ATTGTTCAAG GAAACAACAG CCTTTGTAAC AACTGTACTG CTACTACTTT
        CCTGCGAGAA TAACAAGTTC CTTTGTTGTC GGAAACATTG TTGACATGAC GATGATGAAA
           970         980         990        1000        1010        1020
10     *     *     *     *     *     *     *     *     *     *     *     *
        AACTCTTACA CCTCCTTTTG TTCCCGGTCC ATACTTGTGC ATTGGCACAG GAAGAGGGCC
        TTGAGAATGT GGAGGAAAAC AAGGGCCAGG TATGAACACG TAACCGTGTC CTTCTCCCGG
          1030        1040        1050        1060        1070        1080
       *     *     *     *     *     *     *     *     *     *     *     *
15      TAGCTGCTTT AATCGCTGGA CTTTACAAAA AGAGAACCTA ACCACTACCA CCCTCCTTCC
        ATCGACGAAA TTAGCGACCT GAAATGTTTT TCTCTTGGAT TGGTGATGGT GGGAGGAAGG
          1090        1100        1110        1120        1130        1140
       *        *        *        *        *        *        *        *
        CCTTACTACT TATACTTTTT CCCAAAAAAA AATTTACTTT TTGCCCATTA TTGCACTTTT
20      GGAATGATGA ATATGAAAAA GGGTTTTTTT TTAAATGAAA AACGGGTAAT AACGTGAAAA
          1150        1160        1170        1180        1190        1200
       *        *        *        *        *        *        *        *
        GGCCTTTGTC TGTGTTATTA CCGCTAATTA CATTTTAATT TTCAATCTTG ATAATTTTTA
        CCGGAAACAG ACACAATAAT GGCGATTAAT GTAAAATTAA AAGTTAGAAC TATTAAAAAT
25        1210        1220        1230        1240        1250        1260
       *     *     *     *     *     *     *     *     *     *     *     *
        CTAATCATGC TGCTGTTTTT ACTTTGCCTT CTTTTCTGCT CTGCCTATGC CGCCGTGCCA
        GATTAGTACG ACGACAAAAA TGAAACGGAA GAAAAGACGA GACGGATACG GCGGCACGGT
           1270        1280        1290        1300        1310        1320
30     *     *     *     *     *     *     *     *     *     *     *     *
        GAAAAAACTC TTAACAACCT CGTTCGGGTG TATGCCTTAG TTGGTACCAA TCTATCCCTT
        CTTTTTTGAG AATTGTTGGA GCAAGCCCAC ATACGGAATC AACCATGGTT AGATAGGGAA
          1330        1340        1350        1360        1370        1380
       *     *     *     *     *     *     *     *     *     *     *     *
35      GATTCTATGA AAACTCCTCA GATTGACGAA CTTACTAGTC TTAGCTGGAT TAAACAGGAA
        CTAAGATACT TTTGAGGAGT CTAACTGCTT GAATGATCAG AATCGACCTA ATTTGTCCTT
```

```
1          1390       1400       1410       1420       1430       1440
  *     *     *     *     *     *     *     *     *     *     *     *
   GACAATCCTA ACAAAAACTT ACAATCATTT TTTTTTATTG GTCAAAAACT CTGTGAAGTT
   CTGTTAGGAT TGTTTTTGAA TGTTAGTAAA AAAAAATAAC CAGTTTTTGA GACACTTCAA
5          1450       1460       1470       1480       1490       1500
  *     *     *     *     *     *     *     *     *     *     *     *
   ACCAAAGACA AAATCACTGT TTTTAACTAT TATCCGTTGG AATTTTCCTG CGCTAACGTA
   TGGTTTCTGT TTTAGTGACA AAAATTGATA ATAGGCAACC TTAAAAGGAC GCGATTGCAT
         1510       1520       1530       1540       1550       1560
10 *     *     *     *     *     *     *     *     *     *     *     *
   ACCTTGTATT TGTATAATCT TAAAACTGAC GATTCTGGCC TCTATAATGG AAAGGCCCAT
   TGGAACATAA ACATATTAGA ATTTTGACTG CTAAGACCGG AGATATTACC TTTCCGGGTA
         1570       1580       1590       1600       1610       1620
  *     *     *     *     *     *     *     *     *     *     *     *
15 ACCAAAGAGC TTGAACATAA CACCTATGTT AGGCTTTATG TTATTGACAT TCCTCCGCCT
   TGGTTTCTCG AACTTGTATT GTGGATACAA TCCGAAATAC AATAACTGTA AGGAGGCGGA
         1630       1640       1650       1660       1670       1680
  *     *     *     *     *     *     *     *     *     *     *     *
   AAGTGTGACA TTACTTCACG TTACTTAGGC ATACAGGCTA CTGGGGAAGA TTATTGTTTA
20 TTCACACTGT AATGAAGTGC AATGAATCCG TATGTCCGAT GACCCCTTCT AATAACAAAT
         1690       1700       1710       1720       1730       1740
  *     *     *     *     *     *     *     *     *     *     *     *
   ATTGAAATCA ATTGCACTAA CTCCAAATAC CCAGCTGTGG TTAAATTTAA TGGCAGGCAA
   TAACTTTAGT TAACGTGATT GAGGTTTATG GGTCGACACC AATTTAAATT ACCGTCCGTT
25       1750       1760       1770       1780       1790       1800
  *     *     *     *     *     *     *     *     *     *     *     *
   AGCAACTTCT ACCATTATGT TAGCGAAAAC GGAAACAAAG AACTTCCAAA TTTTTATGAA
   TCGTTGAAGA TGGTAATACA ATCGCTTTTG CCTTTGTTTC TTGAAGGTTT AAAAATACTT
         1810       1820       1830       1840       1850       1860
30 *     *     *     *     *     *     *     *     *     *     *     *
   ACACACATCA CTGTTAATGG TACCCACAAA AGCTTTCACT TTAATTACCC TTTTAACGAC
   TGTGTGTAGT GACAATTACC ATGGGTGTTT TCGAAAGTGA AATTAATGGG AAAATTGCTG
         1870       1880       1890       1900       1910       1920
  *     *     *     *     *     *     *     *     *     *     *     *
35 CTTTGTCAAA CAACCAGCGC TCTACAATAT AATGACAATG TCCAGGTAGT CCTCATTCTT
   GAAACAGTTT GTTGGTCGCG AGATGTTATA TTACTGTTAC AGGTCCATCA GGAGTAAGAA
```

```
1          1930       1940       1950       1960       1970       1980
       *     *     *     *     *     *     *     *     *     *     *     *
        CTCATAGTAG TTGGCTTAAT AATAATTTCC GCTAGTTTAA TATTGCTTTA TTGCCACCGC
        GAGTATCATC AACCGAATTA TTATTAAAGG CGATCAAATT ATAACGAAAT AACGGTGGCG
5          1990       2000       2010       2020       2030       2040
       *     *     *     *     *     *     *     *     *     *     *     *
        AAAAAAATCA AGGCCGAAGT TCAACATCAA CCAGTGCATA TTTGTTTAGA AAAATAAAAT
        TTTTTTTAGT TCCGGCTTCA AGTTGTAGTT GGTCACGTAT AAACAAATCT TTTTATTTTA
              2050       2060       2070       2080       2090       2100
10     *     *     *     *     *     *     *     *     *     *     *     *
        AAAAAAGAAA AGTCATACCA TTGAGGAGAA GAGGACGAAC AGACAGACGG TTAATAGATG
              2110       2120       2130       2140       2150       2160
       *     *     *     *     *     *     *     *     *     *     *     *
        GCCTCCACCA CCTTCGCCGC AGTCTCCCAC CTTGATACGG ATTGTCTTCC CGCCTTGCTG
15      CGGAGGTGGT GGAAGCGGCG TCAGAGGGTG GAACTATGCC TAACAGAAGG GCGGAACGAC
              2170       2180       2190       2200       2210       2220
       *     *     *     *     *     *     *     *     *     *     *     *
        ACTTATCTCA TCTTCACCTC TGTTTGCTGC ACTGCCATCT GCAGCATTGC CACTTTTTTT
        TGAATAGAGT AGAAGTGGAG ACAAACGACG TGACGGTAGA CGTCGTAACG GTGAAAAAAA
20         2230       2240       2250       2260       2270       2280
       *     *     *     *     *     *     *     *     *     *     *     *
        GTGGCCATTT TCCAAACTGC GGACTACCTA TACGTTAGAG TGGCATACTA TCGTCATCAT
        CACCGGTAAA AGGTTTGACG CCTGATGGAT ATGCAATCTC ACCGTATGAT AGCAGTAGTA
              2290       2300       2310       2320       2330       2340
25     *     *     *     *     *     *     *     *     *     *     *     *
        CCCCAATATA GGAACCACGA GGTGGCCGCC CTTCTGTGCC TGTCATGAAA GTTCCTCTTC
        GGGGTTATAT CCTTGGTGCT CCACCGGCGG GAAGACACGG ACAGTACTTT CAAGGAGAAG
             2350       2360       2370       2380       2390       2400
       *     *     *     *     *     *     *     *     *     *     *     *
30      TCTGTCTTAT CCTCCTTCAC AAAGTCCTGG CCAACTGCCA CCTCCACCGG CCCACCGAGT
        AGACAGAATA GGAGGAAGTG TTTCAGGACC GGTTGACGGT GGAGGTGGCC GGGTGGCTCA
              2410       2420       2430       2440       2450       2460
       *     *     *     *     *     *     *     *     *     *     *     *
        TCCTGCGCTG CTACTCAACA GAAACCTCTT CCTTTTGGCT GTACTCCATT ATTTTTATTT
35      AGGACGCGAC GATGAGTTGT CTTTGGAGAA GGAAAACCGA CATGAGGTAA TAAAAATAAA
```

```
1          2470       2480       2490       2500       2510       2520
     *     *     *     *     *     *     *     *     *     *     *     *
      TGATTTTCTT TGCCACCTTT TTGGGATTAC AAATTTACGG CTGCCTTCAC CTGGGCTGGA
      ACTAAAAGAA ACGGTGGAAA AACCCTAATG TTTAAATGCC GACGGAAGTG GACCCGACCT
5          2530       2540       2550       2560       2570       2580
     *     *     *     *     *     *     *     *     *     *     *     *
      TGCATCCTCC-CAACAACCTA CCCAGATTTC CTGGTTTCTT ATTACAGCCC CCGCCGCCCC
      ACGTAGGAGG GTTGTTGGAT GGGTCTAAAG GACCAAAGAA TAATGTCGGG GGCGGCGGGG
           2590       2600       2610       2620       2630       2640
10   *     *     *     *     *     *     *     *     *     *     *     *
      CACCAGCTCC TGTACAGCGC GCTCCATCAG TTATTAGCTA CTTTCATCTT AACTCTGAAG
      GTGGTCGAGG ACATGTCGCG CGAGGTAGTC AATAATCGAT GAAAGTAGAA TTGAGACTTC
           2650       2660       2670       2680       2690       2700
     *     *     *     *     *     *     *     *     *     *     *     *
15    ATGTCTGACC AACTAGAAAT CGACGGGCAG CGCACTGAGC AGCTGATCCT TGCTCGGCGA
      TACAGACTGG TTGATCTTTA GCTGCCCGTC GCGTGACTCG TCGACTAGGA ACGAGCCGCT
           2710       2720       2730       2740       2750       2760
     *     *     *     *     *     *     *     *     *     *     *     *
      AAACTCAAAC AACAAAACCA GGAATTGTTC AACCTTCAAG CCTTACACCA ATGCAAAAAG
20    TTTGAGTTTG TTGTTTTGGT CCTTAACAAG TTGGAAGTTC GGAATGTGGT TACGTTTTTC
           2770       2780       2790       2800       2810       2820
     *     *     *     *     *     *     *     *     *     *     *     *
      GGTCTTTTCT GCCTGGTTAA ACAAGCTGAA CTTTGCTATG ATGTAACCCA ACAGGGGCAT
      CCAGAAAAGA CGGACCAATT TGTTCGACTT GAAACGATAC TACATTGGGT TGTCCCCGTA
25         2830       2840       2850       2860       2870       2880
     *     *     *     *     *     *     *     *     *     *     *     *
      GAGCTATCAT ACACTTTAAA CAAGCAAAGA CAGAGCTTTA TGACTATGGT GGGGGTTAAG
      CTCGATAGTA TGTGAAATTT GTTCGTTTCT GTCTCGAAAT ACTGATACCA CCCCCAATTC
           2890       2900       2910       2920       2930       2940
30   *     *     *     *     *     *     *     *     *     *     *     *
      CCCATTAAGG TTACTCAGCA ATCCGGCCCA GTTGAGGGAA GCATTCTTTG TCAGTGCACC
      GGGTAATTCC AATGAGTCGT TAGGCCGGGT CAACTCCCTT CGTAAGAAAC AGTCACGTGG
           2950       2960       2970       2980       2990       3000
     *     *     *     *     *     *     *     *     *     *     *     *
35    AATTCTGAAT GCATGTACAC TATGGTAAAA ACCCTGTGTG GTCTCAGGGA ACTTCTCCCC
      TTAAGACTTA CGTACATGTG ATACCATTTT TGGGACACAC CAGAGTCCCT TGAAGAGGGG
```

```
1          3010        3020        3030        3040        3050        3060
       *     *     *     *     *     *     *     *     *     *     *     *
        TTTAATTAAA GTTATCTGAT TAATAAAGCT TACCTTAAAT TTGATATCAG TTGTTTGTCA
        AAATTAATTT CAATAGACTA ATTATTTCGA ATGGAATTTA AACTATAGTC AACAAACAGT
5          3070        3080        3090        3100        3110        3120
       *     *     *     *     *     *     *     *     *     *     *     *
        AGTTTTTCCA GCAGCACCAC CTGCCCTTCC TCCCAACTTT CGTAGGGGAT GTGCCAACGG
        TCAAAAAGGT CGTCGTGGTG GACGGGAAGG AGGGTTGAAA GCATCCCCTA CACGGTTGCC
          3130        3140        3150        3160        3170        3180
       *     *     *     *     *     *     *     *     *     *     *     *
10      GCAGCAAACT TTCTCCACGT CCTAAAGGGT ATATCGGTGT TCACCTTTTT ACCCTGACCC
        CGTCGTTTGA AAGAGGTGCA GGATTTCCCA TATAGCCACA AGTGGAAAAA TGGGACTGGG
          3190        3200        3210        3220        3230        3240
       *     *     *     *     *     *     *     *     *     *     *     *
        ACGATCTTCA TCTTGCAGAT GAAAAGAACC AGAATTGAAG ACGACTTCAA CCCCGTCTAC
        TGCTAGAAGT AGAACGTCTA CTTTTCTTGG TCTTAACTTC TGCTGAAGTT GGGGCAGATG
15         3250        3260        3275        3280        3290        3300
       *     *     *     *     *     *     *     *     *     *     *     *
        CCCTATGACA CCTTCTCAAC TCCCAGCATC CCCTATGTAG CTCCGCCCTT CGTTTCTTCT
        GGGATACTGT GGAAGAGTTG AGGGTCGTAG GGGATACATC GAGGCGGGAA GCAAAGAAGA
          3310        3320        3330        3340        3350        3360
       *     *     *     *     *     *     *     *     *     *     *     *
20      GACGGGTTAC AGGAAAAACC CCCAGGAGTT TTAGCACTCA AGTACACTGA CCCCATTACT
        CTGCCCAATG TCCTTTTTGG GGGTCCTCAA AATCGTGAGT TCATGTGACT GGGGTAATGA
          3370
       *     *
        ACCAATGCTA AGC
        TGGTTACGAT TCG
```

25

10. The nucleic acid according to Claim 1 or 2 having a nucleotide sequence of Fig. 4 from base 683 to base 1204.

11. The nucleic acid according to Claim 1 or 2 encoding an amino acid sequence for RL-1 which comprises:

```
Met Lys Ile Cys Val Leu Phe Cys Val Leu Ser Leu Thr Ser Ser Leu Arg
Thr Ser Pro Thr Thr Val Gly Ser Leu Arg Gln Leu Gln Asp Ser Thr Lys
Gly Thr His Gln Thr Leu Tyr Phe Ser Glu Ser Thr Thr Ser Ile Ala Leu
```

30

35

Asn Cys Ser Cys Arg Asn Gln Leu Val Gln Trp Arg Ala Asn Arg Gln Phe
Cys Lys Leu Phe Trp Asp Ala Leu Ile Val Gln Gly Asn Asn Ser Leu Cys
Asn Asn Cys Thr Ala Thr Thr Leu Thr Leu Thr Pro Pro Phe Val Pro Gly
Pro Tyr Leu Cys Ile Gly Thr Gly Arg Gly Pro Ser Cys Phe Asn Arg Trp
Thr Leu Gln Lys Glu Asn Leu Thr Thr Thr Thr Leu Leu Pro Leu Thr Thr
Tyr Thr Phe Ser Gln Lys Lys Ile Tyr Phe Leu Pro Ile Ile Ala Leu Leu
Ala Phe Val Cys Val Ile Thr Ala Asn Tyr Ile Leu Ile Phe Asn Leu Asp
Asn Phe Tyr

12. The nucleic acid according to Claim 1 or 2 having a nucleotide sequence of Fig. 4 from base 1207 to base 2037.

13. The nucleic acid according to Claim 1 of 2 encoding an amino acid sequence for RL-2 which comprises:

Met Leu Leu Phe Leu Leu Cys Leu Leu Phe Cys Ser Ala Tyr Ala Ala Val
Pro Glu Lys Thr Leu Asn Asn Leu Val Arg Val Tyr Ala Leu Val Gly Thr
Asn Leu Ser Leu Asp Ser Met Lys Thr Pro Gln Ile Asp Glu Leu Thr Ser
Leu Ser Trp Ile Lys Gln Glu Asp Asn Pro Asn Lys Asn Leu Gln Ser Phe
Phe Phe Ile Gly Gln Lys Leu Cys Glu Val Thr Lys Asp Lys Ile Thr Val
Phe Asn Tyr Tyr Pro Leu Glu Phe Ser Cys Ala Asn Val Thr Leu Tyr Leu
Tyr Asn Leu Lys Thr Asp Asp Ser Gly Leu Tyr Asn Gly Lys Ala His Thr
Lys Glu Leu Glu His Asn Thr Tyr Val Arg Leu Tyr Val Ile Asp Ile Pro
Pro Pro Lys Cys Asp Ile Thr Ser Arg Tyr Leu Gly Ile Gln Ala Thr Gly
Glu Asp Tyr Cys Leu Ile Glu Ile Asn Cys Thr Asn Ser Lys Tyr Pro Ala
Val Val Lys Phe Asn Gly Arg Gln Ser Asn Phe Tyr His Tyr Val Ser Glu
Asn Gly Asn Lys Glu Leu Pro Asn Phe Tyr Glu Thr His Ile Thr Val Asn
Gly Thr His Lys Ser Phe His Phe Asn Tyr Pro Phe Asn Asp Leu Cys Gln
Thr Thr Ser Ala Leu Gln Tyr Asn Asp Asn Val Gln Val Val Leu Ile Leu
Leu Ile Val Val Gly Leu Ile Ile Ile Ser Ala Ser Leu Ile Leu Leu Tyr
Cys His Arg Lys Lys Ile Lys Ala Glu Val Gln His Gln Pro Val His Ile
Cys Leu Glu Lys

14. The nucleic acid according to Claim 1 or 2 having a nucleotide sequence of Fig. 4 from base 1730 to base 1909.

15. The nucleic acid according to Claim 1 of 2 encoding an amino acid sequence for RL-3 which comprises.

Met Ala Gly Lys Ala Thr Ser Thr Ile Met Leu Ala Lys Thr Glu Thr Lys Asn Phe Gln Ile Phe Met Lys His Thr Ser Leu Leu Met Val Pro Thr Lys Ala Phe Thr Leu Ile Thr Leu Leu Thr Thr Phe Val Lys Gln Pro Ala Leu Tyr Asn Ile Met Thr Met Ser Arg

16. The nucleic acid according to Claim 1 or 2 having a nucleotide sequence of Fig. 4 from base 2056 to base 2328.

17. The nucleic acid according to Claim 1 or 2 encoding an amino acid sequence for RL-4 which comprises:

Met Val Thr Pro Leu Leu Leu Leu Val Cys Leu Pro Ile Ile Tyr Ala Ser Thr Thr Phe Ala Ala Val Ser His Leu Asp Thr Asp Cys Leu Pro Ala Leu Leu Thr Tyr Leu Ile Phe Thr Ser Val Cys Cys Thr Ala Ile Cys Ser Ile Ala Thr Phe Phe Val Ala Ile Phe Gln Thr Ala Asp Tyr Leu Tyr Val Arg Val Ala Tyr Tyr Arg His His Pro Gln Tyr Arg Asn His Glu Val Ala Ala Leu Leu Cys Leu Ser

18. The nucleic acid according to Claim 1 or 2 having a nucleotide sequence of Fig. 4 from base 2325 to base 2648.

19.The nucleic acid according to Claim 1 or 2 encoding an amino acid sequence for RL-5 which compises:

Met Lys Val Pro Leu Leu Cys Leu Ile Leu Leu His Lys Val Leu Ala Asn Cys His Leu His Arg Pro Thr Glu Phe Leu Arg Cys Tyr Ser Thr Glu Thr Ser Ser Phe Trp Leu Tyr Ser Ile Ile Phe Ile Leu Ile Phe Phe Ala Thr Phe Leu Gly Leu Gln Ile Tyr Gly Cys Leu His Leu Gly Trp Met His Pro Pro Asn Asn Leu Pro Arg Phe Pro Gly Phe Leu Leu Gln Pro Pro Pro Pro Pro Pro Ala Pro Val Gln Arg Ala Pro Ser Val Ile Ser Tyr Phe His Leu Asn Ser Glu Asp Val

20. The nucleic acid according to Claim 1 or 2 having a nucleotide sequence of Fig. 4 from base 2641 to base 3009.

21. The nucleic acid according to Claim 1 or 2 encoding an amino acid sequence for RL-6 which comprises:

Met Ser Asp Gln Leu Glu Ile Asp Gly Gln Arg Thr Glu Gln Leu Ile Leu
Ala Arg Arg Lys Leu Lys Gln Gln Asn Gln Glu Leu Phe Asn Leu Gln Ala
Leu His Gln Cys Lys Lys Gly Leu Phe Cys Leu Val Lys Gln Ala Glu Leu
Cys Tyr Asp Val Thr Gln Gln Gly His Glu Leu Ser Tyr Thr Leu Asn Lys
Gln Arg Gln Ser Phe Met Thr Met Val Gly Val Lys Pro Ile Lys Val Thr
Gln Gln Ser Gly Pro Val Glu Gly Ser Ile Leu Cys Gln Cys Thr Asn Ser
Glu Cys Met Tyr Thr Met Val Lys Thr Leu Cys Gly Leu Arg Glu Leu Leu
Pro Phe Asn

22. A replicable expression vector compising the nucleic acid of Claim 1 or 2 operably linked to a nucleotide sequence capable of effecting expression of a polypeptide encoded by any one of said nucleic acids.

23. A recombinant DNA according to Claim 4 having the identifying characteristics of the Ad41 long fiber protein sequence accorded the EMBL accession number X16583.

24. A recombinant DNA according to Claim 7 having the identifying characteristics of the Ad41 short fiber protein sequence accorded the EMBL accession number X17016.

25. A recombinant DNA according to Claim 9 having the identifying characteristics of the Ad41 E3 sequence encoding Ad41 proteins RL-1 to RL-6 accorded the GenBank accession number M33160.

26. A recombinant protein of human enteric adenovirus Type 41 wherein said protein is long fiber protein, short fiber protein, RL-1, RL-2, RL-3, RL-4, RL-5 or RL-6.

27. The recombinant protein of Claim 26 of long fiber protein of human enteric adenovirus Type 41 wherein said protein has an amino acid sequence comprising:

Met Lys Arg Ala Arg Leu Glu Asp Asp Phe Asn Pro
Val Tyr Pro Tyr Glu His Tyr Asn Pro Leu Asp Ile Pro Phe Ile Thr Pro
Pro Phe Ala Ser Ser Asn Gly Leu Gln Glu Lys Pro Pro Gly Val Leu Ser
Leu Gly Thr Gly Leu Asn Ile Asp Glu Asn Gly Asp Leu Ser Ser Asp Ala
Ser Val Glu Val Ser Ala Pro Ile Thr Lys Thr Asn Lys Ile Val Gly Leu
Asn Tyr Thr Lys Pro Leu Ala Leu Arg Ser Asn Ala Leu Thr Leu Ser Tyr
Asn Ala Pro Leu Asn Val Val Asn Asn Asn Leu Ala Leu Asn Ile Ser Gln
Pro Val Thr Val Asn Ala Asn Asn Glu Leu Ser Leu Leu Ile Asp Ala Pro
Leu Asn Ala Asp Thr Gly Thr Leu Arg Leu Gln Ser Ala Ala Pro Leu Gly
Leu Val Asp Lys Thr Leu Lys Val Leu Phe Ser Ser Pro Leu Tyr Leu Asp
Asn Asn Phe Leu Thr Leu Ala Ile Glu Arg Pro Leu Ala Leu Ser Ser Ser
Arg Ala Val Thr Leu Lys Tyr Ser Pro Pro Leu Lys Ile Glu Asn Glu Asn
Leu Thr Leu Ser Thr Gly Gly Pro Phe Thr Val Ser Gly Gly Asn Leu Asn
Leu Thr Thr Ser Ala Pro Leu Ser Val Gln Asn Asn Ser Leu Ser Leu Val
Ile Thr Ser Pro Leu Lys Val Ile Asn Ser Met Leu Ala Val Gly Val Asn
Pro Pro Phe Thr Ile Thr Asp Ser Gly Leu Ala Met Asp Leu Gly Asp Gly
Leu Ala Leu Gly Gly Ser Lys Leu Ile Ile Asn Leu Gly Pro Gly Leu Gln
Met Ser Asn Gly Ala Ile Thr Leu Ala Leu Asp Ala Ala Leu Pro Leu Gln
Tyr Arg Asp Asn Gln Leu Gln Leu Arg Ile Gly Ser Thr Ser Gly Leu Ile
Met Ser Gly Val Thr Gln Thr Leu Asn Val Asn Ala Asn Thr Gly Lys Gly
Leu Ala Val Glu Asn Asn Ser Leu Val Val Lys Leu Gly Asn Gly Leu Arg
Phe Asp Ser Trp Gly Ser Ile Thr Val Ser Pro Thr Thr Thr Thr Pro Thr
Thr Leu Trp Thr Thr Ala Asp Pro Ser Pro Asn Ala Thr Phe Tyr Glu Ser
Leu Asp Ala Lys Val Trp Leu Val Leu Val Lys Cys Asn Gly Met Val Asn
Gly Thr Ile Ser Ile Lys Ala Gln Lys Gly Ile Leu Leu Arg Pro Thr Ala
Ser Phe Ile Ser Phe Val Met Tyr Phe Tyr Ser Asp Gly Thr Trp Arg Lys
Asn Tyr Pro Val Phe Asp Asn Glu Gly Ile Leu Ala Asn Ser Ala Thr Trp
Gly Tyr Arg Gln Gly Gln Ser Ala Asn Thr Asn Val Ser Asn Ala Val Glu
Phe Met Pro Ser Ser Lys Arg Tyr Pro Asn Gln Lys Gly Ser Glu Val Gln
Asn Met Ala Leu Thr Tyr Thr Phe Leu Gln Gly Asp Pro Asn Met Ala Ile
Ser Phe Gln Ser Ile Tyr Asn His Ala Leu Glu Gly Tyr Ser Leu Lys Phe
Thr Trp Arg Val Arg Asn Asn Glu Arg Phe Asp Ile Pro Cys Cys Ser Phe
Ser Tyr Val Thr Glu Gln

28. The recombinant protein of Claim 26 of the short fiber protein of human enteric adenovirus Type 41 wherein said protein has an amino acid sequence comprising:

Met Lys Arg Thr Arg Ile Glu Asp Asp Phe Asn Pro Val Tyr Pro Tyr Asp
Thr Phe Ser Thr Pro Ser Ile Pro Tyr Val Ala Pro Pro Phe Val Ser Ser
Asp Gly Leu Gln Glu Lys Pro Pro Gly Val Leu Ala Leu Lys Tyr Thr Asp
Pro Ile Thr Thr Asn Ala Lys His Glu Leu Thr Leu Lys Leu Gly Ser Asn
Ile Thr Leu Glu Asn Gly Leu Leu Ser Ala Thr Val Pro Thr Val Ser Pro
Pro Leu Thr Asn Ser Asn Asn Ser Leu Gly Leu Ala Thr Ser Ala Pro Ile
Ala Val Ser Ala Asn Ser Leu Thr Leu Ala Thr Ala Ala Pro Leu Thr Val
Ser Asn Asn Gln Leu Ser Ile Asn Ala Gly Arg Gly Leu Val Ile Thr Asn
Asn Ala Leu Thr Val Asn Pro Thr Gly Ala Leu Gly Phe Asn Asn Thr Gly
Ala Leu Gln Leu Asn Ala Ala Gly Gly Met Arg Val Asp Gly Ala Asn Leu
Ile Leu His Val Ala Tyr Pro Phe Glu Ala Ile Asn Gln Leu Thr Leu Arg
Leu Glu Asn Gly Leu Glu Val Thr Ser Gly Gly Lys Leu Asn Val Lys Leu
Gly Ser Gly Leu Gln Phe Asp Ser Asn Gly Arg Ile Ala Ile Ser Asn Ser
Asn Arg Thr Arg Ser Val Pro Ser Leu Thr Thr Ile Trp Ser Ile Ser Pro
Thr Pro Asn Cys Ser Ile Tyr Glu Thr Gln Asp Ala Asn Leu Phe Leu Cys
Leu Thr Lys Asn Gly Ala His Val Leu Gly Thr Ile Thr Ile Lys Gly Leu
Lys Gly Ala Leu Arg Glu Met His Asp Asn Ala Leu Ser Leu Lys Leu Pro
Phe Asp Asn Gln Gly Asn Leu Leu Asn Cys Ala Leu Glu Ser Ser Thr Trp
Arg Tyr Gln Glu Thr Asn Ala Val Ala Ser Asn Ala Leu Thr Phe Met Pro
Asn Ser Thr Val Tyr Pro Arg Asn Lys Thr Ala His Pro Gly Asn Met Leu
Ile Gln Ile Ser Pro Asn Ile Thr Phe Ser Val Val Tyr Asn Glu Ile Asn
Ser Gly Tyr Ala Phe Thr Phe Lys Trp Ser Ala Glu Pro Gly Lys Pro Phe
His Pro Pro Thr Ala Val Phe Cys Tyr Ile Thr Glu Gln

29. The recombinant protein of Claim 26 of E3 RL-1 protein of human adenovirus Type 41 wherein said protein has an amino acid sequence comprising:

Met Lys Ile Cys Val Leu Phe Cys Val Leu Ser Leu Thr Ser Ser Leu Arg Thr Ser Pro Thr Thr Val Gly Ser Leu Arg Gln Leu Gln Asp Ser Thr Lys Gly Thr His Gln Thr Leu Tyr Phe Ser Glu Ser Thr Thr Ser Ile Ala Leu Asn Cys Ser Cys Arg Asn Gln Leu Val Gln Trp Arg Ala Asn Arg Gln Phe Cys Lys Leu Phe Trp Asp Ala Leu Ile Val Gln Gly Asn Asn Ser Leu Cys Asn Asn Cys Thr Ala Thr Thr Leu Thr Leu Thr Pro Pro Phe Val Pro Gly Pro Tyr Leu Cys Ile Gly Thr Gly Arg Gly Pro Ser Cys Phe Asn Arg Trp Thr Leu Gln Lys Glu Asn Leu Thr Thr Thr Thr Leu Leu Pro Leu Thr Thr Tyr Thr Phe Ser Gln Lys Lys Ile Tyr Phe Leu Pro Ile Ile Ala Leu Leu Ala Phe Val Cys Val Ile Thr Ala Asn Tyr Ile Leu Ile Phe Asn Leu Asp Asn Phe Tyr

30. The recombinant protein of Claim 26 of E3 RL-2 protein of human adenovirus Type 41 wherein said protein has an amino acid sequence comprising:

Met Leu Leu Phe Leu Leu Cys Leu Leu Phe Cys Ser Ala Tyr Ala Ala Val Pro Glu Lys Thr Leu Asn Asn Leu Val Arg Val Tyr Ala Leu Val Gly Thr Asn Leu Ser Leu Asp Ser Met Lys Thr Pro Gln Ile Asp Glu Leu Thr Ser Leu Ser Trp Ile Lys Gln Glu Asp Asn Pro Asn Lys Asn Leu Gln Ser Phe Phe Phe Ile Gly Gln Lys Leu Cys Glu Val Thr Lys Asp Lys Ile Thr Val Phe Asn Tyr Tyr Pro Leu Glu Phe Ser Cys Ala Asn Val Thr Leu Tyr Leu Tyr Asn Leu Lys Thr Asp Asp Ser Gly Leu Tyr Asn Gly Lys Ala His Thr Lys Glu Leu Glu His Asn Thr Tyr Val Arg Leu Tyr Val Ile Asp Ile Pro Pro Pro Lys Cys Asp Ile Thr Ser Arg Tyr Leu Gly Ile Gln Ala Thr Gly Glu Asp Tyr Cys Leu Ile Glu Ile Asn Cys Thr Asn Ser Lys Tyr Pro Ala Val Val Lys Phe Asn Gly Arg Gln Ser Asn Phe Tyr His Tyr Val Ser Glu Asn Gly Asn Lys Glu Leu Pro Asn Phe Tyr Glu Thr His Ile Thr Val Asn Gly Thr His Lys Ser Phe His Phe Asn Tyr Pro Phe Asn Asp Leu Cys Gln Thr Thr Ser Ala Leu Gln Tyr Asn Asp Asn Val Gln Val Val Leu Ile Leu Leu Ile Val Val Gly Leu Ile Ile Ile Ser Ala Ser Leu Ile Leu Leu Tyr Cys His Arg Lys Lys Ile Lys Ala Glu Val Gln His Gln Pro Val His Ile Cys Leu Glu Lys

31. The recombinant protein of Claim 26 of E3 R1-3 protein of human adenovirus Type 41 wherein said protein has an amino acid sequence comprising:

Met Ala Gly Lys Ala Thr Ser Thr Ile Met Leu Ala Lys Thr Glu Thr Lys Asn Phe Gln Ile Phe Met Lys His Thr Ser Leu Leu Met Val Pro Thr Lys Ala Phe Thr Leu Ile Thr Leu Leu Thr Thr Phe Val Lys Gln Pro Ala Leu Tyr Asn Ile Met Thr Met Ser Arg

32. The recombinant protein of Claim 26 of E3 R1-4 protein of human adenovirus Type 41 wherein said protein has an amino acid sequence comprising:

Met Val Thr Pro Leu Leu Leu Leu Val Cys Leu Pro Ile Ile Tyr Ala Ser Thr Thr Phe Ala Ala Val Ser His Leu Asp Thr Asp Cys Leu Pro Ala Leu Leu Thr Tyr Leu Ile Phe Thr Ser Val Cys Cys Thr Ala Ile Cys Ser Ile Ala Thr Phe Phe Val Ala Ile Phe Gln Thr Ala Asp Tyr Leu Tyr Val Arg Val Ala Tyr Tyr Arg His His Pro Gln Tyr Arg Asn His Glu Val Ala Ala Leu Leu Cys Leu Ser

33. The recombinant protein of Claim 26 of E3 RL-5 protein of human adenovirus Type 41 wherein said protein has an amino acid sequence comprising:

Met Lys Val Pro Leu Leu Cys Leu Ile Leu Leu His Lys Val Leu Ala Asn Cys His Leu His Arg Pro Thr Glu Phe Leu Arg Cys Tyr Ser Thr Glu Thr Ser Ser Phe Trp Leu Tyr Ser Ile Ile Phe Ile Leu Ile Phe Phe Ala Thr Phe Leu Gly Leu Gln Ile Tyr Gly Cys Leu His Leu Gly Trp Met His Pro Pro Asn Asn Leu Pro Arg Phe Pro Gly Phe Leu Leu Gln Pro Pro Pro Pro Pro Pro Ala Pro Val Gln Arg Ala Pro Ser Val Ile Ser Tyr Phe His Leu Asn Ser Glu Asp Val

34. The recombinant protein of Claim 26 of E3 RL-6 protein of human adenovirus Type 41 wherein said protein has an amino acid sequence comprising:

Met Ser Asp Gln Leu Glu Ile Asp Gly Gln Arg Thr Glu Gln Leu Ile Leu
Ala Arg Arg Lys Leu Lys Gln Gln Asn Gln Glu Leu Phe Asn Leu Gln Ala
Leu His Gln Cys Lys Lys Gly Leu Phe Cys Leu Val Lys Gln Ala Glu Leu
Cys Tyr Asp Val Thr Gln Gln Gly His Glu Leu Ser Tyr Thr Leu Asn Lys
Gln Arg Gln Ser Phe Met Thr Met Val Gly Val Lys Pro Ile Lys Val Thr
Gln Gln Ser Gly Pro Val Glu Gly Ser Ile Leu Cys Gln Cys Thr Asn Ser
Glu Cys Met Tyr Thr Met Val Lys Thr Leu Cys Gly Leu Arg Glu Leu Leu
Pro Phe Asn

35. A polypeptide encoded by the nucleic acid of any one of Claims 1-21.

36. A polypeptide comprising an antigenic fragment of human adenovirus Type 41 long fiber protein, short fiber protein, Rl-1 protein, RL-2 protein, RL-3 protein, RL-4 protein, RL-5 protein or RL-6 protein.

37. Antibodies against a long fiber protein of human adenovirus Type 41, a short fiber protein, RL-1 protein, RL-2 protein, RL-3 protein, RL-4 protein, RL-5 protein or RL-6 protein.

38. Antibodies against the polypeptides of Claims 35 or 36.

39. The antibodies according to Claim 38 which are specific to the tail, shaft or knob region of the Ad41 long fiber protein or short fiber protein.

40. The antibodies according to any one of Claims 37 to 39 wherein said antibodies are monoclonal or polyclonal.

41. A vaccine for immunization against a human adenovirus comprising the administration of an effective amount of at least one of Ad41 long fiber protein, short fiber protein, RL-1, RL-2, RL-3, Rl-4, RL-5 or RL-6 and/or active fragments thereof in association with a conventional vaccine carrier.

42. A vaccine for immunization against a human adenovirus comprising the administration of a mixture of inactivated Ad41 and at least one of recombinant proteins as described in any one of Claims 26 to 34 or active fragments thereof in association with a conventional vaccine carrier.

43. The vaccine according to Claim 41 or 42 wherein the human adenovirus is Ad41 or Ad40.

44. The vaccine according to any one of Claims 41 to 43 wherein the dosage effective range is about 0.001-100 mg antigen/kg body.

45. A host organism or cell transformed by the nucleic acid of any one of Claims 1 to 21.

46. A host organism or cell according to Claim 45 wherein the host is yeast or bacterium.

47. A method of detecting or diagnosing human adenovirus comprising contacting serum, tissue, or tissue extracts of an individual to be tested with an antibody against Ad41 long fiber protein, short fiber protein, RL-1 protein, RL-2 protein, RL-3 protein, RL-4 protein, RL-5 protein or RL-6 protein or an active fragment thereof, for a time and under conditions necessary to form an antibody-antigen complex, and detecting any resultant antibody-antigen complex.

48. A method for detecting human adenovirus Type 41, human adenovirus Ad40 or any adenovirus antigenically or structurally similar to human Ad41 in infected cells in a sample comprising lysing said cells, fixing the DNA of the infected calls and detecting the DNA containing said long fiber protein gene, short fiber protein gene or E3 gene by a specific probe nucleic acid wherein said probe nucleic acid is DNA, cDNA, recombinant DNA or RNA.

49. A compartmentalized kit for detection of human adenovirus type 41 comprising at least one first container adapted to contain an antibody having specificity for said Ad41 long fiber protein, short fiber protein or E3 proteins, RL-1 to RL-6 and at least one second container adapted to contain a reporter molecule capable of detecting the antibody of said first container.

50. The kit of Claim 49 wherein the reporter molecule is a radioisotope, an enzyme, a fluorescent molecule, a chemiluminescent molecule or a bioluminescent molecule.

```
1          10         20         30         40         50         60
     *     *     *     *     *     *     *     *     *     *
     CCCGGGCAAC   ATGCTCATCC  AAATCTCGCC  TAACATCACC  TTCAGTGTCG  TCTACAACGA
     GGGCCCGTTG   TACGAGTAGG  TTTAGAGCGG  ATTGTAGTGG  AAGTCACAGC  AGATGTTGCT
5    SmaI

          70         80         90        100        110        120
     *     *     *     *     *     *     *     *     *     *
     GATAAACAGT   GGGTATGCTT  TTACTTTTAA  ATGGTCAGCC  GAACCGGGAA  AACCTTTTCA
10   CTATTTGTCA   CCCATACGAA  AATGAAAATT  TACCAGTCGG  CTTGGCCCTT  TTGGAAAAGT

         130        140        150        160        170        180
     *     *     *     *     *     *     *     *     *     *
     CCCACCTACC   GCTGTATTTT  GCTACATAAC  TGAACAATAA  AATCATTGCA  GGCACAATCT
15   GGGTGGATGG   CGACATAAAA  CGATGTATTG  ACTTGTTATT  TTAGTAACGT  CCGTGTTAGA
         190        200        210        220        230
     *     *     *     *     *     *     *     *     *     *
     TCGCATTTCT   TTTTTTCCAG  ATG AAA CGA GCC AGA CTT GAA GAT GAC TTC AAC CCC
     AGCGTAAAGA   AAAAAAGGTC  TAC TTT GCT CGG TCT GAA CTT CTA CTG AAG TTG GGG
20                            Met Lys Arg Ala Arg Leu Glu Asp Asp Phe Asn Pro
                                  60.6 KD FIBER PROTEIN
         240        250        260        270        280
     *     *     *     *     *     *     *     *     *     *
     GTC TAC CCT TAC GAA CAC TAC AAT CCC CTT GAC ATC CCA TTT ATT ACA CCC
25   CAG ATG GGA ATG CTT GTG ATG TTA GGG GAA CTG TAG GGT AAA TAA TGT GGG
     Val Tyr Pro Tyr Glu His Tyr Asn Pro Leu Asp Ile Pro Phe Ile Thr Pro
                                  60.6 KD FIBER PROTEIN
              290        300        310        320        330
     *     *     *     *     *     *     *     *     *     *
30
     CCG TTT GCC TCC TCC AAC GGC TTG CAA GAA AAA CCA CCG GGA GTC CTC AGC
     GGC AAA CGG AGG AGG TTG CCG AAC GTT CTT TTT GGT GGC CCT CAG GAG TCG
     Pro Phe Ala Ser Ser Asn Gly Leu Gln Glu Lys Pro Pro Gly Val Leu Ser
                                  60.6 KD FIBER PROTEIN
35
```

```
1   340         350         360         370         380
    *     *     *     *     *     *     *     *     *     *

    CTG AAA TAC ACT GAT CCA CTT ACA ACC AAA AAC GGG GCT TTA ACC TTA AAA
5   GAC TTT ATG TGA CTA GGT GAA TGT TGG TTT TTG CCC CGA AAT TGG AAT TTT
    Leu Lys Tyr Thr Asp Pro Leu Thr Thr Lys Asn Gly Ala Leu Thr Leu Lys
                          60.6 KD FIBER PROTEIN
    390         400         410         420         430         440
    *     *     *     *     *     *     *     *     *     *

10  CTG GGC ACG GGA CTA AAC ATT GAT GAA AAT GGA GAT CTT TCT TCA GAT GCT
    GAC CCG TGC CCT GAT TTG TAA CTA CTT TTA CCT CTA GAA AGA AGT CTA CGA
    Leu Gly Thr Gly Leu Asn Ile Asp Glu Asn Gly Asp Leu Ser Ser Asp Ala
                          60.6 KD FIBER PROTEIN
          450         460         470         480         490
15  *     *     *     *     *     *     *     *     *     *

    AGC GTG GAA GTT AGC GCC CCT ATT ACT AAA ACC AAC AAA ATC GTA GGT TTA
    TCG CAC CTT CAA TCG CGG GGA TAA TGA TTT TGG TTG TTT TAG CAT CCA AAT
    Ser Val Glu Val Ser Ala Pro Ile Thr Lys Thr Asn Lys Ile Val Gly Leu
                          60.6 KD FIBER PROTEIN
20        500         510         520         530         540
    *     *     *     *     *     *     *     *     *     *

    AAT TAC ACT AAA CCT CTC GCC CTG CGA AGT AAC GCG CTC ACT CTT TCT TAC
    TTA ATG TGA TTT GGA GAG CGG GAC GCT TCA TTG CGC GAG TGA GAA AGA ATG
25  Asn Tyr Thr Lys Pro Leu Ala Leu Arg Ser Asn Ala Leu Thr Leu Ser Tyr
                          60.6 KD FIBER PROTEIN
          550         560         570         580         590
    *     *     *     *     *     *     *     *     *     *

30  AAC GCA CCC TTA AAC GTA GTA AAT AAC AAT TTA GCT TTA AAT ATC TCA CAA
    TTG CGT GGG AAT TTG CAT CAT TTA TTG TTA AAT CGA AAT TTA TAG AGT GTT
    Asn Ala Pro Leu Asn Val Val Asn Asn Asn Leu Ala Leu Asn Ile Ser Gln
                          60.6 KD FIBER PROTEIN

35
```

```
1          600        610        620        630        640
     *     *     *     *     *     *     *     *     *     *

     CCT GTC  ACT GTT AAT GCA AAC AAC GAA CTT TCT CTC TTA ATA GAC GCC CCA
5    GGA CAG  TGA CAA TTA CGT TTG TTG CTT GAA AGA GAG AAT TAT CTG CGG GGT
     Pro Val  Thr Val Asn Ala Asn Asn Glu Leu Ser Leu Leu Ile Asp Ala Pro
                                60.6 KD FIBER PROTEIN
               650        660        670        680        690
     *     *     *     *     *     *     *     *     *     *
10   CTT AAT  GCT GAC ACG GGC ACT CTT CGC CTT CAA AGT GCT GCA CCT CTT GGA
     GAA TTA  CGA CTG TGC CCG TGA GAA GCG GAA GTT TCA CGA CGT GGA GAA CCT
     Leu Asn  Ala Asp Thr Gly Thr Leu Arg Leu Gln Ser Ala Ala Pro Leu Gly
                                60.6 KD FIBER PROTEIN
               700        710        720        730        740
15   *     *     *     *     *     *     *     *     *     *

     CTA GTG  GAC AAA ACA CTA AAA GTT TTG TTT TCT AGC CCC CTC TAT CTA GAT
     GAT CAC  CTG TTT TGT GAT TTT CAA AAC AAA AGA TCG GGG GAG ATA GAT CTA
     Leu Val  Asp Lys Thr Leu Lys Val Leu Phe Ser Ser Pro Leu Tyr Leu Asp
20                              60.6 KD FIBER PROTEIN
     750        760        770        780        790
     *     *     *     *     *     *     *     *     *     *
     AAT AAC  TTT CTT ACA CTA GCC ATT GAA CGC CCG CTA GCT CTA TCC AGT AGC
     TTA TTG  AAA GAA TGT GAT CGG TAA CTT GCG GGC GAT CGA GAT AGG TCA TCG
25   Asn Asn  Phe Leu Thr Leu Ala Ile Glu Arg Pro Leu Ala Leu Ser Ser Ser
                                60.6 KD FIBER PROTEIN
     800        810        820        830        840
     *     *     *     *     *     *     *     *     *     *
     AGA GCA  GTG ACC CTT AAG TAT TCA CCA CCT TTA AAA ATA GAA AAC GAA AAC
30   TCT CGT  CAC TGG GAA TTC ATA AGT GGT GGA AAT TTT TAT CTT TTG CTT TTG
     Arg Ala  Val Thr Leu Lys Tyr Ser Pro Pro Leu Lys Ile Glu Asn Glu Asn
                                60.6 KD FIBER PROTEIN
```

Figure 1 - Cont'd

35

```
1   850          860          870          880          890
    *      *     *      *     *      *     *      *     *      *
    TTA ACC CTA AGC ACA GGC GGG CCT TTT ACT GTA AGC GGG GGA AAT CTA AAC
    AAT TGG GAT TCG TGT CCG CCC GGA AAA TGA CAT TCG CCC CCT TTA GAT TTG
5   Leu Thr Leu Ser Thr Gly Gly Pro Phe Thr Val Ser Gly Gly Asn Leu Asn
                          60.6 KD FIBER PROTEIN
    900          910          920          930          940          950
    *      *     *      *     *      *     *      *     *      *
    TTA ACA ACA TCG GCA CCT CTC TCC GTG CAA AAC AAC TCT CTC TCC TTA GTC
10  AAT TGT TGT AGC CGT GGA GAG AGG CAC GTT TTG TTG AGA GAG AGG AAT CAG
    Leu Thr Thr Ser Ala Pro Leu Ser Val Gln Asn Asn Ser Leu Ser Leu Val
                          60.6 KD FIBER PROTEIN
               960          970          980          990          1000
    *      *     *      *     *      *     *      *     *      *
15  ATT ACT TCT CCT TTA AAA GTT ATT AAT TCT ATG TTA GCC GTT GGG GTT AAC
    TAA TGA AGA GGA AAT TTT CAA TAA TTA AGA TAC AAT CGG CAA CCC CAA TTG
    Ile Thr Ser Pro Leu Lys Val Ile Asn Ser Met Leu Ala Val Gly Val Asn
                          60.6 KD FIBER PROTEIN
            1010         1020         1030         1040         1050
20  *      *     *      *     *      *     *      *     *      *
    CCG CCT TTT ACC ATC ACT GAC TCT GGA TTA GCT ATG GAC TTA GGA GAC GGT
    GGC GGA AAA TGG TAG TGA CTG AGA CCT AAT CGA TAC CTG AAT CCT CTG CCA
    Pro Pro Phe Thr Ile Thr Asp Ser Gly Leu Ala Met Asp Leu Gly Asp Gly
25
                          60.6 KD FIBER PROTEIN
```

Figure 1 - Cont'd

30

35

```
1          1060       1070       1080       1090       1100
           *          *          *          *          *          *          *          *          *
           CTT GCA CTA GGT GGC TCT AAG TTA ATA ATC AAT CTT GGT CCA GGT TTA CAA
           GAA CGT GAT CCA CCG AGA TTC AAT TAT TAG TTA GAA CCA GGT CCA AAT GTT
5          Leu Ala Leu Gly Gly Ser Lys Leu Ile Ile Asn Leu Gly Pro Gly Leu Gln
                                   60.6 KD FIBER PROTEIN
                   1110       1120       1130       1140       1150
                   *          *          *          *          *          *          *          *          *
                   ATG TCT AAT GGA GCT ATT ACT TTA GCA CTA GAT GCA GCG CTG CCT TTG CAA
10                 TAC AGA TTA CCT CGA TAA TGA AAT CGT GAT CTA CGT CGC GAC GGA AAC GTT
                   Met Ser Asn Gly Ala Ile Thr Leu Ala Leu Asp Ala Ala Leu Pro Leu Gln
                                   60.6 KD FIBER PROTEIN
                   1160       1170       1180       1190       1200
                   *          *          *          *          *          *          *          *          *
15                 TAT AGA GAC AAC CAA CTT CAA CTC AGA ATT GGC TCA ACA TCT GGC TTA ATT
                   ATA TCT CTG TTG GTT GAA GTT GAG TCT TAA CCG AGT TGT AGA CCG AAT TAA
                   Tyr Arg Asp Asn Gln Leu Gln Leu Arg Ile Gly Ser Thr Ser Gly Leu Ile
                                   60.6 KD FIBER PROTEIN
                   1210       1220       1230       1240       1250
20                 *          *          *          *          *          *          *          *          *
                   ATG AGC GGA GTA ACA CAA ACA TTA AAC GTC AAT GCC AAT ACC GGC AAA GGT
                   TAC TCG CCT CAT TGT GTT TGT AAT TTG CAG TTA CGG TTA TGG CCG TTT CCA
                   Met Ser Gly Val Thr Gln Thr Leu Asn Val Asn Ala Asn Thr Gly Lys Gly
                                   60.6 KD FIBER PROTEIN
25                 1260       1270       1280       1290       1300
                   *          *          *          *          *          *          *          *          *
                   CTT GCT GTT GAA AAC AAC TCA CTA GTT GTT AAG CTT GGG AAC GGT CTT CGC
                   GAA CGA CAA CTT TTG TTG AGT GAT CAA CAA TTC GAA CCC TTG CCA GAA GCG
                   Leu Ala Val Glu Asn Asn Ser Leu Val Val Lys Leu Gly Asn Gly Leu Arg
30                                 60.6 KD FIBER PROTEIN
                   1310       1320       1330       1340       1350
                   *          *          *          *          *          *          *          *          *
                   TTT GAT AGC TGG GGA AGC ATA ACT GTC TCG CCT ACT ACC ACT ACC CCT ACC
                   AAA CTA TCG ACC CCT TCG TAT TGA CAG AGC GGA TGA TGG TGA TGG GGA TGG
35                 Phe Asp Ser Trp Gly Ser Ile Thr Val Ser Pro Thr Thr Thr Thr Pro Thr
                                   60.6 KD FIBER PROTEIN
```

Figure 1 - Cont'd

```
1          1360        1370        1380        1390        1400
           *     *     *     *     *     *     *     *     *     *
           ACC CTA TGG ACC ACC GCA GAC CCA TCA CCT AAC GCC ACT TTT TAT GAA TCA
           TGG GAT ACC TGG TGG CGT CTG GGT AGT GGA TTG CGG TGA AAA ATA CTT AGT
5          Thr Leu Trp Thr Thr Ala Asp Pro Ser Pro Asn Ala Thr Phe Tyr Glu Ser
                                  60.6 KD FIBER PROTEIN
           1410        1420        1430        1440        1450        1460
           *     *     *     *     *     *     *     *     *     *     *     *
           CTA GAC GCC AAA GTG TGG CTA GTT TTA GTA AAA TGC AAC GGC ATG GTT AAC
10         GAT CTG CGG TTT CAC ACC GAT CAA AAT CAT TTT ACG TTG CCG TAC CAA TTG
           Leu Asp Ala Lys Val Trp Leu Val Leu Val Lys Cys Asn Gly Met Val Asn
                                  60.6 KD FIBER PROTEIN
                      1470        1480        1490        1500        1510
           *     *     *     *     *     *     *     *     *     *     *     *
15         GGG ACC ATA TCC ATT AAA GCT CAG AAA GGC ATT TTA CTT AGA CCT ACA GCT
           CCC TGG TAT AGG TAA TTT CGA GTC TTT CCG TAA AAT GAA TCT GGA TGT CGA
           Gly Thr Ile Ser Ile Lys Ala Gln Lys Gly Ile Leu Leu Arg Pro Thr Ala
                                  60.6 KD FIBER PROTEIN
                      1520        1530        1540        1550        1560
20         *     *     *     *     *     *     *     *     *     *     *     *
           AGT TTT ATT TCC TTT GTC ATG TAT TTC TAC AGC GAT GGA ACA TGG AGA AAA
           TCA AAA TAA AGG AAA CAG TAC ATA AAG ATG TCG CTA CCT TGT ACC TCT TTT
           Ser Phe Ile Ser Phe Val Met Tyr Phe Tyr Ser Asp Gly Thr Trp Arg Lys
                                  60.6 KD FIBER  PROTEIN
25                    1570        1580        1590        1600        1610
           *     *     *     *     *     *     *     *     *     *     *     *
           AAC TAT CCC GTG TTT GAC AAC GAA GGG ATA CTA GCA AAC AGT GCC ACG TGG
           TTG ATA GGG CAC AAA CTG TTG CTT CCC TAT GAT CGT TTG TCA CGG TGC ACC
           Asn Tyr Pro Val Phe Asp Asn Glu Gly Ile Leu Ala Asn Ser Ala Thr Trp
30                                60.6 KD FIBER PROTEIN
                      1620        1630        1640        1650        1660
           *     *     *     *     *     *     *     *     *     *     *     *
           GGT TAT CGA CAA GGA CAG TCT GCC AAC ACT AAC GTT TCT AAT GCT GTA GAA
           CCA ATA GCT GTT CCT GTC AGA CGG TTG TGA TTG CAA AGA TTA CGA CAT CTT
35         Gly Tyr Arg Gln Gly Gln Ser Ala Asn Thr Asn Val Ser Asn Ala Val Glu
                                  60.6 KD FIBER PROTEIN
```

Figure 1 - Cont'd

```
1          1670       1680       1690       1700       1710
     *     *     *     *     *     *     *     *     *     *     *     *
     TTT ATG  CCT AGC TCT AAA AGA TAT CCC AAT CAA AAA GGT TCT GAA GTT CAG
     AAA TAC  GGA TCG AGA TTT TCT ATA GGG TTA GTT TTT CCA AGA CTT CAA GTC
5    Phe Met  Pro Ser Ser Lys Arg Tyr Pro Asn Gln Lys Gly Ser Glu Val Gln
                                60.6 KD FIBER PROTEIN
          1720       1730       1740       1750       1760
     *         *         *         *         *         *         *         *
     AAC ATG  GCT CTT ACC TAC ACT TTT TTG CAA GGT GAT CCT AAC ATG GCC ATA
10   TTG TAC  CGA GAA TGG ATG TGA AAA AAC GTT CCA CTA GGA TTG TAC CGG TAT
     Asn Met  Ala Leu Thr Tyr Thr Phe Leu Gln Gly Asp Pro Asn Met Ala Ile
                                60.6 KD FIBER PROTEIN

          1770       1780       1790       1800       1810
15   *         *         *         *         *         *         *         *
     TCC TTT  CAG AGT ATT TAT AAT CAT GCA TTA GAA GGC TAC TCA TTA AAA TTT
     AGG AAA  GTC TCA TAA ATA TTA GTA CGT AAT CTT CCG ATG AGT AAT TTT AAA
     Ser Phe  Gln Ser Ile Tyr Asn His Ala Leu Glu Gly Tyr Ser Leu Lys Phe
                                60.6 KD FIBER PROTEIN
20        1820       1830       1840       1850       1860
     *         *         *         *         *         *         *         *
     ACC TGG  CGC GTT CGA AAT AAT GAA CGT TTT GAC ATC CCC TGC TGC TCA TTT
     TGG ACC  GCG CAA GCT TTA TTA CTT GCA AAA CTG TAG GGG ACG ACG AGT AAA
     Thr Trp  Arg Val Arg Asn Asn Glu Arg Phe Asp Ile Pro Cys Cys Ser Phe
25                              60.6 KD FIBER PROTEIN
          1870       1880       1890       1900       1910       1920
     *         *         *         *         *         *         *         *
     TCT TAT  GTA ACA GAA CAA TAA  A  ATATTGTTGT  TTTTGTTTTT  ATAACTTTAT
     AGA ATA  CAT TGT CTT GTT ATT  T  TATAACAACA  AAAACAAAAA  TATTGAAATA
30   Ser Tyr  Val Thr Glu Gln End
                                60.6 KD FIBER PROTEIN
        1930
     *   *   *
     TGATACTTTT  ACAGAATTC
35   ACTATGAAAA  TGTCTTAAG
                 EcoRI
```

```
1           10          20          30          40          50          60
    *     *     *     *     *     *     *     *     *     *     *     *
    GATATCAGTT  GTTTGTCAAG  TTTTTCCAGC  AGCACCACCT  GCCCTTCCTC  CCAACTTTCG
    CTATAGTCAA  CAAACAGTTC  AAAAAGGTCG  TCGTGGTGGA  CGGGAAGGAG  GGTTGAAAGC
5           70          80          90          100         110         120
    *     *     *     *     *     *     *     *     *     *     *     *
    TAGGGGATGT  GCCAACGGGC  AGCAAACTTT  CTCCACGTCC  TAAAGGGTAT  ATCGGTGTTC
    ATCCCCTACA  CGGTTGCCCG  TCGTTTGAAA  GAGGTGCAGG  ATTTCCCATA  TAGCCACAAG
            130         140         150         160         170         180
10  *     *     *     *     *     *     *     *     *     *     *     *
    ACCTTTTTAC  CCTGACCCAC  GATCTTCATC  TTGCAGATGA  AAAGAACCAG  AATTGAAGAC
    TGGAAAAATG  GGACTGGGTG  CTAGAAGTAG  AACGTCTACT  TTTCTTGGTC  TTAACTTCTG
            190         200         210         220         230         240
    *     *     *     *     *     *     *     *     *     *     *     *
15  GACTTCAACC  CCGTCTACCC  CTATGACACC  TTCTCAACTC  CCAGCATCCC  CTATGTAGCT
    CTGAAGTTGG  GGCAGATGGG  GATACTGTGG  AAGAGTTGAG  GGTCGTAGGG  GATACATCGA
            250         260         270         280         290         300
    *     *     *     *     *     *     *     *     *     *     *     *
    CCGCCCTTCG  TTTCTTCTGA  CGGGTTACAG  GAAAAACCCC  CAGGAGTTTT  AGCACTCAAG
20  GGCGGGAAGC  AAAGAAGACT  GCCCAATGTC  CTTTTTGGGG  GTCCTCAAAA  TCGTGAGTTC
            310         320         330         340         350         360
    *     *     *     *     *     *     *     *     *     *     *     *
    TACACTGACC  CCATTACTAC  CAATGCTAAG  CATGAGCTTA  CTTTAAAACT  TGGAAGCAAC
    ATGTGACTGG  GGTAATGATG  GTTACGATTC  GTACTCGAAT  GAAATTTTGA  ACCTTCGTTG
25          370         380         390         400         410         420
    *     *     *     *     *     *     *     *     *     *     *     *
    ATAACTTTAG  AAAATGGGTT  ACTTTCGGCC  ACAGTTCCCA  CTGTTTCTCC  TCCCCTTACA
    TATTGAAATC  TTTTACCCAA  TGAAAGCCGG  TGTCAAGGGT  GACAAAGAGG  AGGGGAATGT
            430         440         450         460         470         480
30  *     *     *     *     *     *     *     *     *     *     *     *
    AACAGTAACA  ACTCCCTGGG  TTTAGCCACA  TCCGCTCCCA  TAGCTGTATC  AGCTAACTCT
    TTGTCATTGT  TGAGGGACCC  AAATCGGTGT  AGGCGAGGGT  ATCGACATAG  TCGATTGAGA
```

35

Figure 2

```
1          490         500         510         520         530         540
       *     *     *     *     *     *     *     *     *     *     *     *
        CTCACATTGG CCACCGCCGC ACCACTGACA GTAAGCAACA ACCAGCTTAG TATTAACGCG
        GAGTGTAACC GGTGGCGGCG TGGTGACTGT CATTCGTTGT TGGTCGAATC ATAATTGCGC
5          550         560         570         580         590         600
       *     *     *     *     *     *     *     *     *     *     *     *
        GGCAGAGGTT TAGTTATAAC TAACAATGCC TTAACAGTTA ATCCTACCGG AGCGCTAGGT
        CCGTCTCCAA ATCAATATTG ATTGTTACGG AATTGTCAAT TAGGATGGCC TCGCGATCCA
          610         620         630         640         650         660
10     *     *     *     *     *     *     *     *     *     *     *     *
        TTCAATAACA CAGGAGCTTT ACAATTAAAT GCTGCAGGAG GAATGAGAGT GGACGGTGCC
        AAGTTATTGT GTCCTCGAAA TGTTAATTTA CGACGTCCTC CTTACTCTCA CCTGCCACGG
          670         680         690         700         710         720
       *     *     *     *     *     *     *     *     *     *     *     *
15      AACTTAATTC TTCATGTAGC ATATCCCTTT GAAGCAATCA ACCAGCTAAC ACTGCGATTA
        TTGAATTAAG AAGTACATCG TATAGGGAAA CTTCGTTAGT TGGTCGATTG TGACGCTAAT
          730         740         750         760         770         780
       *     *     *     *     *     *     *     *     *     *     *     *
        GAAAACGGGT TAGAAGTAAC CAGCGGAGGA AAGCTTAACG TTAAGTTGGG ATCAGGCCTC
20      CTTTTGCCCA ATCTTCATTG GTCGCCTCCT TTCGAATTGC AATTCAACCC TAGTCCGGAG
          790         800         810         820         830         840
       *     *     *     *     *     *     *     *     *     *     *     *
        CAATTTGACA GTAACGGACG CATTGCTATT AGTAATAGCA ACCGAACTCG AAGTGTACCA
        GTTAAACTGT CATTGCCTGC GTAACGATAA TCATTATCGT TGGCTTGAGC TTCACATGGT
25        850         860         870         880         890         900
       *     *     *     *     *     *     *     *     *     *     *     *
        TCCCTCACTA CCATTTGGTC TATCTCGCCT ACGCCTAACT GCTCCATTTA TGAAACCCAA
        AGGGAGTGAT GGTAAACCAG ATAGAGCGGA TGCGGATTGA CGAGGTAAAT ACTTTGGGTT
          910         920         930         940         950         960
30     *     *     *     *     *     *     *     *     *     *     *     *
        GATGCAAACC TATTTCTTTG TCTAACTAAA AACGGAGCTC ACGTATTAGG TACTATAACA
        CTACGTTTGG ATAAAGAAAC AGATTGATTT TTGCCTCGAG TGCATAATCC ATGATATTGT
          970         980         990        1000        1010        1020
       *     *     *     *     *     *     *     *     *     *     *     *
35      ATCAAAGGTC TTAAAGGAGC ACTGCGGGAA ATGCACGATA ACGCTCTATC TTTAAAACTT
        TAGTTTCCAG AATTTCCTCG TGACGCCCTT TACGTGCTAT TGCGAGATAG AAATTTTGAA
```

Figure 2 - Cont'd

```
1          1030       1040       1050       1060       1070       1080
       *     *     *     *     *     *     *     *     *     *     *     *
        CCCTTTGACA ATCAGGGAAA TTTACTTAAC TGTGCCTTGG AATCATCCAC CTGGCGTTAC
        GGGAAACTGT TAGTCCCTTT AAATGAATTG ACACGGAACC TTAGTAGGTG GACCGCAATG
5          1090       1100       1110       1120       1130       1140
       *     *     *     *     *     *     *     *     *     *     *     *
        CAGGAAACCA ACGCAGTGGC CTCTAATGCC TTAACATTTA TGCCCAACAG TACAGTGTAT
        GTCCTTTGGT TGCGTCACCG GAGATTACGG AATTGTAAAT ACGGGTTGTC ATGTCACATA
             1150       1160       1170       1180       1190       1200
10     *     *     *     *     *     *     *     *     *     *     *     *
        CCACGAAACA AAACCGCTCA CCCGGGCAAC ATGCTCATCC AAATCTCGCC TAACATCACC
        GGTGCTTTGT TTTGGCGAGT GGGCCCGTTG TACGAGTAGG TTTAGAGCGG ATTGTAGTGG
             1210       1220       1230       1240       1250       1260
       *     *     *     *     *     *     *     *     *     *     *     *
15      TTCAGTGTCG TCTACAACGA GATAAACAGT GGGTATGCTT TTACTTTTAA ATGGTCAGCC
        AAGTCACAGC AGATGTTGCT CTATTTGTCA CCCATACGAA AATGAAAATT TACCAGTCGG
             1270       1280       1290       1300       1310       1320
       *     *     *     *     *     *     *     *     *     *     *     *
        GAACCGGGAA AACCTTTTCA CCCACCTACC GCTGTATTTT GCTACATAAC TGAACAATAA
20      CTTGGCCCTT TTGGAAAAGT GGGTGGATGG CGACATAAAA CGATGTATTG ACTTGTTATT
             1330       1340       1350       1360       1370       1380
       *     *     *     *     *     *     *     *     *     *     *     *
        AATCATTGCA GGCACAATCT TCGCATTTCT TTTTTTCCAG ATGAAACGAG CCAGACTTGA
        TTAGTAACGT CCGTGTTAGA AGCGTAAAGA AAAAAAGGTC TACTTTGCTC GGTCTGAACT
25           1390       1400
              *     *     *     *
        AGATGACTTC AACCCCGTCT    AC
        TCTACTGAAG TTGGGGCAGA    TG
```

30

35

Figure 2 - Cont'd

```
1   Met Lys Arg Thr Arg Ile Glu Asp Asp Phe Asn Pro Val Tyr Pro Tyr Asp
    Thr Phe Ser Thr Pro Ser Ile Pro Tyr Val Ala Pro Pro Phe Val Ser Ser
    Asp Gly Leu Gln Glu Lys Pro Pro Gly Val Leu Ala Leu Lys Tyr Thr Asp
    Pro Ile Thr Thr Asn Ala Lys His Glu Leu Thr Leu Lys Leu Gly Ser Asn
5   Ile Thr Leu Glu Asn Gly Leu Leu Ser Ala Thr Val Pro Thr Val Ser Pro
    Pro Leu Thr Asn Ser Asn Asn Ser Leu Gly Leu Ala Thr Ser Ala Pro Ile
    Ala Val Ser Ala Asn Ser Leu Thr Leu Ala Thr Ala Ala Pro Leu Thr Val
    Ser Asn Asn Gln Leu Ser Ile Asn Ala Gly Arg Gly Leu Val Ile Thr Asn
    Asn Ala Leu Thr Val Asn Pro Thr Gly Ala Leu Gly Phe Asn Asn Thr Gly
10  Ala Leu Gln Leu Asn Ala Ala Gly Gly Met Arg Val Asp Gly Ala Asn Leu
    Ile Leu His Val Ala Tyr Pro Phe Glu Ala Ile Asn Gln Leu Thr Leu Arg
    Leu Glu Asn Gly Leu Glu Val Thr Ser Gly Gly Lys Leu Asn Val Lys Leu
    Gly Ser Gly Leu Gln Phe Asp.Ser Asn Gly Arg Ile Ala Ile.Ser Asn Ser
    Asn Arg Thr Arg Ser Val Pro Ser Leu Thr Thr Ile Trp Ser Ile Ser Pro
15  Thr Pro Asn Cys Ser Ile Tyr Glu Thr Gln Asp Ala Asn Leu Phe Leu Cys
    Leu Thr Lys Asn Gly Ala His Val Leu Gly Thr Ile Thr Ile Lys Gly Leu
    Lys Gly Ala Leu Arg Glu Met His Asp Asn Ala Leu Ser Leu Lys Leu Pro
    Phe Asp Asn Gln Gly Asn Leu Leu Asn Cys Ala Leu Glu Ser Ser Thr Trp
    Arg Tyr Gln Glu Thr Asn Ala Val Ala Ser Asn Ala Leu Thr Phe Met Pro
20  Asn Ser Thr Val Tyr Pro Arg Asn Lys Thr Ala His Pro Gly Asn Met Leu
    Ile Gln Ile Ser Pro Asn Ile Thr Phe Ser Val Val Tyr Asn Glu Ile Asn
    Ser Gly Tyr Ala Phe Thr Phe Lys Trp Ser Ala Glu Pro Gly Lys Pro Phe
    His Pro Pro Thr Ala Val Phe Cys Tyr Ile Thr Glu Gln
```

25

30

35

Figure 3

```
1           10          20          30          40          50          60
    *       *       *       *       *       *       *       *       *       *
    GAATTCGCGC  CACTCGAAAC CAAATTTTGC TGGAGCAAGC TGCCCTGACC TCCACCCCGC
    CTTAAGCGCG  GTGAGCTTTG GTTTAAAACG ACCTCGTTCG ACGGGACTGG AGGTGGGGCG
5
           70          80          90         100         110         120
    *       *       *       *       *       *       *       *       *       *
    GAAGTCAATT  GAACCCGCCC AATTGGCCCG CTGCCCAGGT GTATCAGGAA AACCCCGCTC
    CTTCAGTTAA  CTTGGGCGGG TTAACCGGGC GACGGGTCCA CATAGTCCTT TTGGGGCGAG
10
          130         140         150         160         170         180
    *       *       *       *       *       *       *       *       *       *
    CGACCACAGT  TCTCCTGCCA CGCGACGCTG AGGCCGAAGT CCAAATGACT AACTCCGGAG
    GCTGGTGTCA  AGAGGACGGT GCGCTGCGAC TCCGGCTTCA GGTTTACTGA TTGAGGCCTC
15
          190         200         210         220         230         240
    *       *       *       *       *       *       *       *       *       *
    CGCAATTAGC  GGGCGGATCC AGACACGTCA GGTTCAGAGG TCGGTCCTCG CCCTACTCTC
    GCGTTAATCG  CCCGCCTAGG TCTGTGCAGT CCAAGTCTCC AGCCAGGAGC GGGATGAGAG
20
          250         260         270         280         290         300
    *       *       *       *       *       *       *       *       *       *
    CAGGTCCTAT  AAAGAGGCTG ATTATCCGAG GCCGGGGTAT CCAGCTCAAC GACGAAGTGG
    GTCCAGGATA  TTTCTCCGAC TAATAGGCTC CGGCCCCATA GGTCGAGTTG CTGCTTCACC
25
          310         320         330         340         350         360
    *       *       *       *       *       *       *       *       *       *
    TGAGCTCCTT  AACCGGTCTC CGACCTGACG GAGTTTTCCA GCTTGGAGGT GCCGGCCGCT
    ACTCGAGGAA  TTGGCCAGAG GCTGGACTGC CTCAAAAGGT CGAACCTCCA CGGCCGGCGA
30
    370     380         390         400         410         420
    *       *       *       *       *       *       *       *       *       *
    CCTCCTTCAC  TCCTCGCCAG GCGTACCTGA CACTCCAGAG CTCTTCTTCC CAGCCTCGCT
    GGAGGAAGTG  AGGAGCGGTC CGCATGGACT GTGAGGTCTC GAGAAGAAGG GTCGGAGCGA
35
```

Figure 4

```
1          430        440        450        460        470        480
           *    *     *    *     *    *     *    *     *    *     *    *
           CCGGCGGCAT   TGGAACCCTC CAGTTTGTGG AGGAGTTTGT ACCCTCCGTT TACTTCAACC
           GGCCGCCGTA   ACCTTGGGAG GTCAAACACC TCCTCAAACA TGGGAGGCAA ATGAAGTTGG
5
           490        500        510        520        530        540
           *    *     *    *     *    *     *    *     *    *     *    *
            CATTCTCGGG CGCTCCTGGT CTTTACCCAG ACGACTTCAT CCCAAACTAC GACGCGGTGA
            GTAAGAGCCC GCGAGGACCA GAAATGGGTC TGCTGAAGTA GGGTTTGATG CTGCGCCACT
10
                   550        560        570        580        590        600
                   *    *     *    *     *    *     *    *     *    *     *    *
            GCGAATCTGT GGACGGCTAC GACTGAATCC CAATGGTGCG TCCGTGACTG TGTGGCTGCA
            CGCTTAGACA CCTGCCGATG CTGACTTAGG GTTACCACGC AGGCACTGAC ACACCGACGT
15
                   610        620        630        640        650        660
                   *    *     *    *     *    *     *    *     *    *     *    *
            ACATCTACAT CGGCGCCGTA ATCCTTGCTA CTTTGTCTGA AAAGTCTGTG ATTTTTACTT
            TGTAGATGTA GCCGCGGCAT TAGGAACGAT GAAACAGACT TTTCAGACAC TAAAAATGAA
20
                   670        680        690        700        710        720
                   *    *     *    *     *    *     *    *     *    *     *    *
            ACCGCTCCAG CGCTTGGATT ACATGAAGAT CTGTGTTCTT TTTTGTGTGC TAAGTTTAAC
            TGGCGAGGTC GCGAACCTAA TGTACTTCTA GACACAAGAA AAAACACACG ATTCAAATTG
25
                   730        740        750        760        770        780
                   *    *     *    *     *    *     *    *     *    *     *    *
            AAGTAGCCTA AGGACTTCAC CTACAACCGT TGGTTCCTTA CGTCAGCTAC AAGATTCCAC
            TTCATCGGAT TCCTGAAGTG GATGTTGGCA ACCAAGGAAT GCAGTCGATG TTCTAAGGTG
30
                   790        800        810        820        830        840
                   *    *     *    *     *    *     *    *     *    *     *    *
            CAAAGGTACA CACCAAACTC TTTATTTTTC TGAGTCTACC ACTTCTATTG CACTTAACTG
            GTTTCCATGT GTGGTTTGAG AAATAAAAAG ACTCAGATGG TGAAGATAAC GTGAATTGAC
35
```

Figure 4- Cont'd

```
1          850        860        870        880        890        900
     *     *     *     *     *     *     *     *     *     *
      TTCTTGTCGT AACCAACTCG TTCAGTGGCG CGCTAACAGA CAATTTTGCA AACTATTTTG
      AAGAACAGCA TTGGTTGAGC AAGTCACCGC GCGATTGTCT GTTAAAACGT TTGATAAAAC
5
           910        920        930        940        950        960
     *     *     *     *     *     *     *     *     *     *
      GGACGCTCTT ATTGTTCAAG GAAACAACAG CCTTTGTAAC AACTGTACTG CTACTACTTT
      CCTGCGAGAA TAACAAGTTC CTTTGTTGTC GGAAACATTG TTGACATGAC GATGATGAAA
10
           970        980        990       1000       1010       1020
     *     *     *     *     *     *     *     *     *     *
      AACTCTTACA CCTCCTTTTG TTCCCGGTCC ATACTTGTGC ATTGGCACAG GAAGAGGGCC
      TTGAGAATGT GGAGGAAAAC AAGGGCCAGG TATGAACACG TAACCGTGTC CTTCTCCCGG
15
          1030       1040       1050        106       1070       1080
     *     *     *     *     *     *     *     *     *     *
      TAGCTGCTTT AATCGCTGGA CTTTACAAAA AGAGAACCTA ACCACTACCA CCCTCCTTCC
      ATCGACGAAA TTAGCGACCT GAAATGTTTT TCTCTTGGAT TGGTGATGGT GGGAGGAAGG
20
          1090       1100       1110       1120       1130       1140
     *     *     *     *     *     *     *     *     *     *
      CCTTACTACT TATACTTTTT CCCAAAAAAA AATTTACTTT TTGCCCATTA TTGCACTTTT
      GGAATGATGA ATATGAAAAA GGGTTTTTTT TTAAATGAAA AACGGGTAAT AACGTGAAAA
25
          1150       1160       1170       1180       1190       1200
     *     *     *     *     *     *     *     *     *     *
      GGCCTTTGTC TGTGTTATTA CCGCTAATTA CATTTTAATT TTCAATCTTG ATAATTTTTA
      CCGGAAACAG ACACAATAAT GGCGATTAAT GTAAAATTAA AAGTTAGAAC TATTAAAAAT
30
          1210       1220       1230       1240       1250       1260
     *     *     *     *     *     *     *     *     *     *
      CTAATCATGC TGCTGTTTTT ACTTTGCCTT CTTTTCTGCT CTGCCTATGC CGCCGTGCCA
      GATTAGTACG ACGACAAAAA TGAAACGGAA GAAAAGACGA GACGGATACG GCGGCACGGT
35
```

Figure 4 - Con'd

```
1          1270       1280       1290       1300       1310       1320
       *      *      *      *      *      *      *      *      *      *
    GAAAAAACTC TTAACAACCT CGTTCGGGTG TATGCCTTAG TTGGTACCAA TCTATCCCTT
    CTTTTTTGAG AATTGTTGGA GCAAGCCCAC ATACGGAATC AACCATGGTT AGATAGGGAA
5
           1330       1340       1350       1360       1370       1380
       *      *      *      *      *      *      *      *      *      *
    GATTCTATGA AAACTCCTCA GATTGACGAA CTTACTAGTC TTAGCTGGAT TAAACAGGAA
    CTAAGATACT TTTGAGGAGT CTAACTGCTT GAATGATCAG AATCGACCTA ATTTGTCCTT
10         1390       1400       1410       1420       1430       1440
       *      *      *      *      *      *      *      *      *      *
    GACAATCCTA ACAAAAACTT ACAATCATTT TTTTTTATTG GTCAAAAACT CTGTGAAGTT
    CTGTTAGGAT TGTTTTTGAA TGTTAGTAAA AAAAAATAAC CAGTTTTTGA GACACTTCAA

15         1450       1460       1470       1480       1490       1500
       *      *      *      *      *      *      *      *      *      *
    ACCAAAGACA AAATCACTGT TTTTAACTAT TATCCGTTGG AATTTTCCTG CGCTAACGTA
    TGGTTTCTGT TTTAGTGACA AAAATTGATA ATAGGCAACC TTAAAAGGAC GCGATTGCAT

20         1510       1520       1530       1540       1550       1560
       *      *      *      *      *      *      *      *      *      *
    ACCTTGTATT TGTATAATCT TAAAACTGAC GATTCTGGCC TCTATAATGG AAAGGCCCAT
    TGGAACATAA ACATATTAGA ATTTTGACTG CTAAGACCGG AGATATTACC TTTCCGGGTA

25         1570       1580       1590       1600       1610       1620
       *      *      *      *      *      *      *      *      *      *
    ACCAAAGAGC TTGAACATAA CACCTATGTT AGGCTTTATG TTATTGACAT TCCTCCGCCT
    TGGTTTCTCG AACTTGTATT GTGGATACAA TCCGAAATAC AATAACTGTA AGGAGGCGGA

30         1630       1640       1650       1660       1670       1680
       *      *      *      *      *      *      *      *      *      *
    AAGTGTGACA TTACTTCACG TTACTTAGGC ATACAGGCTA CTGGGGAAGA TTATTGTTTA
    TTCACACTGT AATGAAGTGC AATGAATCCG TATGTCCGAT GACCCCTTCT AATAACAAAT
```

35 Figure 4 - Cont'd

```
1690        1700        1710        1720        1730        1740
*           *           *           *           *           *
ATTGAAATCA  ATTGCACTAA  CTCCAAATAC  CCAGCTGTGG  TTAAATTTAA  TGGCAGGCAA
TAACTTTAGT  TAACGTGATT  GAGGTTTATG  GGTCGACACC  AATTTAAATT  ACCGTCCGTT

1750        1760        1770        1780        1790        1800
*           *           *           *           *           *
AGCAACTTCT  ACCATTATGT  TAGCGAAAAC  GGAAACAAAG  AACTTCCAAA  TTTTTATGAA
TCGTTGAAGA  TGGTAATACA  ATCGCTTTTG  CCTTTGTTTC  TTGAAGGTTT  AAAAATACTT

1810        1820        1830        1840        1850        1860
*           *           *           *           *           *
ACACACATCA  CTGTTAATGG  TACCCACAAA  AGCTTTCACT  TTAATTACCC  TTTTAACGAC
TGTGTGTAGT  GACAATTACC  ATGGGTGTTT  TCGAAAGTGA  AATTAATGGG  AAAATTGCTG

1870        1880        1890        1900        1910        1920
*           *           *           *           *           *
CTTTGTCAAA  CAACCAGCGC  TCTACAATAT  AATGACAATG  TCCAGGTAGT  CCTCATTCTT
GAAACAGTTT  GTTGGTCGCG  AGATGTTATA  TTACTGTTAC  AGGTCCATCA  GGAGTAAGAA

1930        1940        1950        1960        1970        1980
*           *           *           *           *           *
CTCATAGTAG  TTGGCTTAAT  AATAATTTCC  GCTAGTTTAA  TATTGCTTTA  TTGCCACCGC
GAGTATCATC  AACCGAATTA  TTATTAAAGG  CGATCAAATT  ATAACGAAAT  AACGGTGGCG

1990        2000        2010        2020        2030        2040
*           *           *           *           *           *
AAAAAAATCA  AGGCCGAAGT  TCAACATCAA  CCAGTGCATA  TTTGTTTAGA  AAAATAAAAT
TTTTTTTAGT  TCCGGCTTCA  AGTTGTAGTT  GGTCACGTAT  AAACAAATCT  TTTTATTTTA

2050        2060        2070        2080        2090        2100
*           *           *           *           *           *
TTTTTTCTTT  TCAGTATGGT  AACTCCTCTT  CTCCTGCTTG  TCTGTCTGCC  AATTATCTAC
AAAAAAGAAA  AGTCATACCA  TTGAGGAGAA  GAGGACGAAC  AGACAGACGG  TTAATAGATG
```

Figure 4 - Cont'd

```
1          2110       2120       2130       2140       2150       2160
       *      *      *      *      *      *      *      *      *      *
    GCCTCCACCA CCTTCGCCGC AGTCTCCCAC CTTGATACGG ATTGTCTTCC CGCCTTGCTG
    CGGAGGTGGT GGAAGCGGCG TCAGAGGGTG GAACTATGCC TAACAGAAGG GCGGAACGAC
5
           2170       2180       2190       2200       2210       2220
       *      *      *      *      *      *      *      *      *      *
    ACTTATCTCA TCTTCACCTC TGTTTGCTGC ACTGCCATCT GCAGCATTGC CACTTTTTTT
    TGAATAGAGT AGAAGTGGAG ACAAACGACG TGACGGTAGA CGTCGTAACG GTGAAAAAAA
10
           2230       2240       2250       2260       2270       2280
       *      *      *      *      *      *      *      *      *      *
    GTGGCCATTT TCCAAACTGC GGACTACCTA TACGTTAGAG TGGCATACTA TCGTCATCAT
    CACCGGTAAA AGGTTTGACG CCTGATGGAT ATGCAATCTC ACCGTATGAT AGCAGTAGTA
15
           2290       2300       2310       2320       2330       2340
       *      *      *      *      *      *      *      *      *      *
    CCCCAATATA GGAACCACGA GGTGGCCGCC CTTCTGTGCC TGTCATGAAA GTTCCTCTTC
    GGGGTTATAT CCTTGGTGCT CCACCGGCGG GAAGACACGG ACAGTACTTT CAAGGAGAAG
20
           2350       2360       2370       2380       2390       2400
       *      *      *      *      *      *      *      *      *      *
    TCTGTCTTAT CCTCCTTCAC AAAGTCCTGG CCAACTGCCA CCTCCACCGG CCCACCGAGT
    AGACAGAATA GGAGGAAGTG TTTCAGGACC GGTTGACGGT GGAGGTGGCC GGGTGGCTCA
25
           2410       2420       2430       2440       2450       2460
       *      *      *      *      *      *      *      *      *      *
    TCCTGCGCTG CTACTCAACA GAAACCTCTT CCTTTTGGCT GTACTCCATT ATTTTTATTT
    AGGACGCGAC GATGAGTTGT CTTTGGAGAA GGAAAACCGA CATGAGGTAA TAAAAATAAA
30
           2470       2480       2490       2500       2510       2520
       *      *      *      *      *      *      *      *      *      *
    TGATTTTCTT TGCCACCTTT TTGGGATTAC AAATTTACGG CTGCCTTCAC CTGGGCTGGA
    ACTAAAAGAA ACGGTGGAAA AACCCTAATG TTTAAATGCC GACGGAAGTG GACCCGACCT
35
```

Figure 4- Cont'd

```
1          2530       2540       2550       2560       2570       2580
       *      *      *      *      *      *      *      *      *      *
    TGCATCCTCC CAACAACCTA CCCAGATTTC CTGGTTTCTT ATTACAGCCC CCGCCGCCCC
    ACGTAGGAGG GTTGTTGGAT GGGTCTAAAG GACCAAAGAA TAATGTCGGG GGCGGCGGGG
5
           2590       2600       2610       2620       2630       2640
       *      *      *      *      *      *      *      *      *      *
    CACCAGCTCC TGTACAGCGC GCTCCATCAG TTATTAGCTA CTTTCATCTT AACTCTGAAG
    GTGGTCGAGG ACATGTCGCG CGAGGTAGTC AATAATCGAT GAAAGTAGAA TTGAGACTTC
10
           2650       2660       2670       2680       2690       2700
       *      *      *      *      *      *      *      *      *      *
    ATGTCTGACC AACTAGAAAT CGACGGGCAG CGCACTGAGC AGCTGATCCT TGCTCGGCGA
    TACAGACTGG TTGATCTTTA GCTGCCCGTC GCGTGACTCG TCGACTAGGA ACGAGCCGCT
15
           2710       2720       2730       2740       2750       2760
       *      *      *      *      *      *      *      *      *      *
    AAACTCAAAC AACAAAACCA GGAATTGTTC AACCTTCAAG CCTTACACCA ATGCAAAAAG
    TTTGAGTTTG TTGTTTTGGT CCTTAACAAG TTGGAAGTTC GGAATGTGGT TACGTTTTTC
20
           2770       2780       2790       2800       2810       2820
       *      *      *      *      *      *      *      *      *      *
    GGTCTTTTCT GCCTGGTTAA ACAAGCTGAA CTTTGCTATG ATGTAACCCA ACAGGGGCAT
    CCAGAAAAGA CGGACCAATT TGTTCGACTT GAAACGATAC TACATTGGGT TGTCCCCGTA
25
           2830       2840       2850       2860       2870       2880
       *      *      *      *      *      *      *      *      *      *
    GAGCTATCAT ACACTTTAAA CAAGCAAAGA CAGAGCTTTA TGACTATGGT GGGGGTTAAG
    CTCGATAGTA TGTGAAATTT GTTCGTTTCT GTCTCGAAAT ACTGATACCA CCCCCAATTC
30
           2890       2900       2910       2920       2930       2940
       *      *      *      *      *      *      *      *      *      *
    CCCATTAAGG TTACTCAGCA ATCCGGCCCA GTTGAGGGAA GCATTCTTTG TCAGTGCACC
    GGGTAATTCC AATGAGTCGT TAGGCCGGGT CAACTCCCTT CGTAAGAAAC AGTCACGTGG
35
```

Figure 4 - Cont'd

```
1          2950       2960       2970       2980       2990       3000
       *      *      *      *      *      *      *      *      *      *
        AATTCTGAAT GCATGTACAC TATGGTAAAA ACCCTGTGTG GTCTCAGGGA ACTTCTCCCC
        TTAAGACTTA CGTACATGTG ATACCATTTT TGGGACACAC CAGAGTCCCT TGAAGAGGGG
5
           3010       3020       3030       3040       3050       3060
       *      *      *      *      *      *      *      *      *      *
        TTTAATTAAA GTTATCTGAT TAATAAAGCT TACCTTAAAT TTGATATCAG TTGTTTGTCA
        AAATTAATTT CAATAGACTA ATTATTTCGA ATGGAATTTA AACTATAGTC AACAAACAGT
10
           3070       3080       3090       3100       3110       3120
       *      *      *      *      *      *      *      *      *      *
        AGTTTTTCCA GCAGCACCAC CTGCCCTTCC TCCCAACTTT CGTAGGGGAT GTGCCAACGG
        TCAAAAAGGT CGTCGTGGTG GACGGGAAGG AGGGTTGAAA GCATCCCCTA CACGGTTGCC
15
           3130       3140       3150       3160       3170       3180
       *      *      *      *      *      *      *      *      *      *
        GCAGCAAACT TTCTCCACGT CCTAAAGGGT ATATCGGTGT TCACCTTTTT ACCCTGACCC
        CGTCGTTTGA AAGAGGTGCA GGATTTCCCA TATAGCCACA AGTGGAAAAA TGGGACTGGG
20
           3190       3200       3210       3220       3230       3240
       *      *      *      *      *      *      *      *      *      *
        ACGATCTTCA TCTTGCAGAT GAAAAGAACC AGAATTGAAG ACGACTTCAA CCCCGTCTAC
        TGCTAGAAGT AGAACGTCTA CTTTTCTTGG TCTTAACTTC TGCTGAAGTT GGGGCAGATG
25
           3250       3260       3270       3280       3290       3300
       *      *      *      *      *      *      *      *      *      *
        CCCTATGACA CCTTCTCAAC TCCCAGCATC CCCTATGTAG CTCCGCCCTT CGTTTCTTCT
        GGGATACTGT GGAAGAGTTG AGGGTCGTAG GGGATACATC GAGGCGGGAA GCAAAGAAGA
30
```

Figure 4 - Cont'd

35

```
1          3310        3320        3330        3340        3350        3360
       *       *       *       *       *       *       *       *       *
    GACGGGTTAC  AGGAAAAACC  CCCAGGAGTT  TTAGCACTCA  AGTACACTGA  CCCCATTACT
    CTGCCCAATG  TCCTTTTTGG  GGGTCCTCAA  AATCGTGAGT  TCATGTGACT  GGGGTAATGA
5
          3370
        *     *
    ACCAATGCTA   AGC
    TGGTTACGAT   TCG
10
```

Figure - Cont'd

15

20

25

30

35

Met Lys Ile Cys Val Leu Phe Cys Val Leu Ser Leu Thr Ser Ser Leu Arg
Thr Ser Pro Thr Thr Val Gly Ser Leu Arg Gln Leu Gln Asp Ser Thr Lys
Gly Thr His Gln Thr Leu Tyr Phe Ser Glu Ser Thr Thr Ser Ile Ala Leu
Asn Cys Ser Cys Arg Asn Gln Leu Val Gln Trp Arg Ala Asn Arg Gln Phe
Cys Lys Leu Phe Trp Asp Ala Leu Ile Val Gln Gly Asn Asn Ser Leu Cys
Asn Asn Cys Thr Ala Thr Thr Leu Thr Leu Thr Pro Pro Phe Val Pro Gly
Pro Tyr Leu Cys Ile Gly Thr Gly Arg Gly Pro Ser Cys Phe Asn Arg Trp
Thr Leu Gln Lys Glu Asn Leu Thr Thr Thr Thr Leu Leu Pro Leu Thr Thr
Tyr Thr Phe Ser Gln Lys Lys Ile Tyr Phe Leu Pro Ile Ile Ala Leu Leu
Ala Phe Val Cys Val Ile Thr Ala Asn Tyr Ile Leu Ile Phe Asn Leu Asp
Asn Phe Tyr

Figure 5

Met Leu Leu Phe Leu Leu Cys Leu Leu Phe Cys Ser Ala Tyr Ala Ala Val
Pro Glu Lys Thr Leu Asn Asn Leu Val Arg Val Tyr Ala Leu Val Gly Thr
Asn Leu Ser Leu Asp Ser Met Lys Thr Pro Gln Ile Asp Glu Leu Thr Ser
Leu Ser Trp Ile Lys Gln Glu Asp Asn Pro Asn Lys Asn Leu Gln Ser Phe
Phe Phe Ile Gly Gln Lys Leu Cys Glu Val Thr Lys Asp Lys Ile Thr Val
Phe Asn Tyr Tyr Pro Leu Glu Phe Ser Cys Ala Asn Val Thr Leu Tyr Leu
Tyr Asn Leu Lys Thr Asp Asp Ser Gly Leu Tyr Asn Gly Lys Ala His Thr
Lys Glu Leu Glu His Asn Thr Tyr Val Arg Leu Tyr Val Ile Asp Ile Pro
Pro Pro Lys Cys Asp Ile Thr Ser Arg Tyr Leu Gly Ile Gln Ala Thr Gly
Glu Asp Tyr Cys Leu Ile Glu Ile Asn Cys Thr Asn Ser Lys Tyr Pro Ala
Val Val Lys Phe Asn Gly Arg Gln Ser Asn Phe Tyr His Tyr Val Ser Glu
Asn Gly Asn Lys Glu Leu Pro Asn Phe Tyr Glu Thr His Ile Thr Val Asn
Gly Thr His Lys Ser Phe His Phe Asn Tyr Pro Phe Asn Asp Leu Cys Gln
Thr Thr Ser Ala Leu Gln Tyr Asn Asp Asn Val Gln Val Val Leu Ile Leu
Leu Ile Val Val Gly Leu Ile Ile Ile Ser Ala Ser Leu Ile Leu Leu Tyr
Cys His Arg Lys Lys Ile Lys Ala Glu Val Gln His Gln Pro Val His Ile
Cys Leu Glu Lys

Figure 5

1 Met Ala Gly Lys Ala Thr Ser Thr Ile Met Leu Ala Lys Thr Glu Thr Lys
Asn Phe Gln Ile Phe Met Lys His Thr Ser Leu Leu Met Val Pro Thr Lys
Ala Phe Thr Leu Ile Thr Leu Leu Thr Thr Phe Val Lys Gln Pro Ala Leu
Tyr Asn Ile Met Thr Met Ser Arg

Figure 7

```
1   Met Val  Thr Pro Leu Leu Leu Leu Val Cys Leu Pro Ile Ile Tyr Ala Ser
    Thr Thr  Phe Ala Ala Val Ser His Leu Asp Thr Asp Cys Leu Pro Ala Leu
    Leu Thr  Tyr Leu Ile Phe Thr Ser Val Cys Cys Thr Ala Ile Cys Ser Ile
    Ala Thr  Phe Phe Val Ala Ile Phe Gln Thr Ala Asp Tyr Leu Tyr Val Arg
5   Val Ala  Tyr Tyr Arg His His Pro Gln Tyr Arg Asn His Glu Val Ala Ala
    Leu Leu  Cys Leu Ser
```

Figure 8

1 Met Lys Val Pro Leu Leu Cys Leu Ile Leu Leu His Lys Val Leu Ala Asn
Cys His Leu His Arg Pro Thr Glu Phe Leu Arg Cys Tyr Ser Thr Glu Thr
Ser Ser Phe Trp Leu Tyr Ser Ile Ile Phe Ile Leu Ile Phe Phe Ala Thr
Phe Leu Gly Leu Gln Ile Tyr Gly Cys Leu His Leu Gly Trp Met His Pro
5 Pro Asn Asn Leu Pro Arg Phe Pro Gly Phe Leu Leu Gln Pro Pro Pro Pro
Pro Pro Ala Pro Val Gln Arg Ala Pro Ser Val Ile Ser Tyr Phe His Leu
Asn Ser Glu Asp Val

10

15

20

25

30

35

Figure 9

1 Met Ser Asp Gln Leu Glu Ile Asp Gly Gln Arg Thr Glu Gln Leu Ile Leu
Ala Arg Arg Lys Leu Lys Gln Gln Asn Gln Glu Leu Phe Asn Leu Gln Ala
Leu His Gln Cys Lys Lys Gly Leu Phe Cys Leu Val Lys Gln Ala Glu Leu
Cys Tyr Asp Val Thr Gln Gln Gly His Glu Leu Ser Tyr Thr Leu Asn Lys
5 Gln Arg Gln Ser Phe Met Thr Met Val Gly Val Lys Pro Ile Lys Val Thr
Gln Gln Ser Gly Pro Val Glu Gly Ser Ile Leu Cys Gln Cys Thr Asn Ser
Glu Cys Met Tyr Thr Met Val Lys Thr Leu Cys Gly Leu Arg Glu Leu Leu
Pro Phe Asn

10

15

20

25

30

35

Figure 10



Protein coding regions in the E3-fiber area of the human enteric adenovirus type 41 Tak (map position of fragment shown: 74% to 92%)

FIG. II

INTERNATIONAL SEARCH REPORT

International Application No PCT/US90/06887

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) [3]

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC(5):C12Q 1/70;C12Q 1/00;G01N 33/53;C07H 15/12, 17/00;C12N 15/00;C12P 21/06; C12N 5/00; C12Q 1/68; A61K 39/00 U.S. CL. 435/5,7.1,240.1,69.1,172.3; 530/350,387; 424/88; 536/27

II. FIELDS SEARCHED

Minimum Documentation Searched [4]

Classification System	Classification Symbols
U.S. CL.:	435/5, 7.2, 240.1, 69.1, 252.3, 172.3, 240.2; 424/88,93, 92; 536/27; 536/350, 387

Documentation Searched other than Minimum Documentation to the Extent that such Documents are included in the Fields Searched [5]

Automated Patent Search, As well as Dialog and STN Commercial Databases

III. DOCUMENTS CONSIDERED TO BE RELEVANT [14]

Category *	Citation of Document, [16] with indication, where appropriate, of the relevant passages [17]	Relevant to Claim No. [18]
P,Y	US, A, 4,888,170 (CURTISS, III) 19 December 1989 (see col. 6. 11. 6-31)	1-46
Y	US, A, 4,855,224 (BERMAN et al.) 08 August 1989 (See col. 8-10).	1-47, 49
Y	J. Gen. Virol. Vol. 70, issued 1989 Toogood et al., "The Adenovirus Type 40 Hexon: Sequence Predicted Structure and relationship to Other Adenovirus Hexons", pp. 3203-3214, see entire document.	1-21, 26-36
Y	Nucleic Acids Research, Vol. 17, No. 22, issued 25 November 1989. Pieniazek et al. "Sequence of human enteric adenovirus type 41 Tak fiber protein gene", page 9474, see entire document.	1-21

* Special categories of cited documents: [15]

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search [2]	Date of Mailing of this International Search Report [2]
28 March 1991	18 APR 1991
International Searching Authority [1]	Signature of Authorized Officer [20]
ISA/US	Bradley L. Sisson

Form PCT/ISA/210 (second sheet) (May 1986)